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ABSTRACT: 
Fas Ligand (FasL) binds to the Fas receptor to induce apoptosis or activate other 
signaling pathways. FasL can also transduce "reverse signais" and thus participate in 
bidirectional signaling. The FasL intracellular domain contains consensus sequences for 
phosphorylation and a proline rich protein interaction domain. This latter region of FasL 
has previously been implicated in FasL reverse signaling and regulation of FasL surface 
expression. In this report, we sought to identify novel FasL interacting proteins to help 
understand signaling through and trafficking of this death factor Using mass 
spectrometry, we identified sorting nexin 18, adaptin ~, Grh2, PACSIN2 and PACSIN3 
as FasL interacting proteins. RNAi mediated knockdown of Grh2 significantly reduced 
the surface expression of FasL and increased its expression intracellularly. Our data 
show that Grb2 con troIs the suhcellular localization of FasL. AlI other proteins 
identified in our screen could be classified as trafficking-associated proteins, highlighting 
the complex regulation of the surface expression of this death factor. 
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RÉSUMÉ: 
La protéine Fas Ligand (FasL) se lie au récepteur Fas afin d'induire l'apoptose ou 
activer d'autres voies de signalisation. La protéine FasL est aussi impliquée dans la 
signalisation rétrograde et participe à une signalisation bidirectionnelle. Le domaine 
intracellulaire de FasL contient une séquence consensus de phosphorylation ainsi qu'un 
domaine d'interaction protéique riche en proline. Ce domaine a précédemment été 
impliqué dans la signalisation rétrograde de FasL et dans la régulation de son expression 
à la surface cellulaire. Dans cette thèse, nous désirions identifier de nouvelles 
interactions protéiques avec FasL afin de contribuer à la compréhension du trafic 
cellulaire et de la signalisation de ce facteur apoptotique. Grâce à la spectrométrie de 
masse, nous avons identifié Sorting Nexin 18, Adaptin ~,PACSIN2, Grb2 et PACSIN3 
comme étant des protéines interagissant avec FasL. En utilisant la méthode de l'ARN 
par interférence, nous avons diminué l'expression de Grb2 et observé que l'expression de 
FasL à la surface cellulaire a été significativement réduite alors que son expression 
intracellulaire a été augmentée. Nos résultats démontrent que Grb2 est impliquée dans le 
contrôle de la localisation subcellulaire de FasL. Les autres protéines identifiées dans 
notre criblage pourraient être classifiées comme protéines associées au trafic cellulaire, 
suggérant ainsi la complexité de la régulation de ce facteur apoptotique à la surface 
cellulaire. 
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Introduction and Objectives 
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LITERA TURE REVIEW: 
PARTI: Fas 
Fas: The mole cule 
The discovery of the Fas molecule arose from the observation that a specific 
antibody (termed anti-Fas) secreted from aB ceIl clone, created by immunizing mice 
with human fibroblast cells, was cytolytic to human cells in culture [1,2]. Nanogram 
quantities of anti-Fas antibodies arrested proliferation, and induced DNA fragmentation 
and morphological changes consistent with programmed ceIl death, or apoptosis [2]. In 
the early 1990s, the Fas antigen, hereafter caIled Fas, was cloned from a human T 
lymphoma cDNA library [3]. Today Fas is known to be a 327 amino acid, type 1 
transmembrane protein and a member of the Tumor Necrosis Factor ReceptorlNerve 
Growth Factor Receptor (TNFRINGFR) superfamily of cytokine receptors. Membership 
in this superfamily is defined based on the presence of cysteine rich pseudo-repeats (also 
known as cysteine rich domains; CRDs) , and Fas possesses three such extracellular 
CRDs [4]. The N-terminal CRD, CRD1, confers the ability of Fas to self-trimerize in the 
absence of ligand and is also known as the pre-ligand assembly domain (PLAD) [5,6] AlI 
three CRDs of the Fas extraceIlular domain are required for binding to FasL [7]. 
Mutagenesis of the Fas intracellular domain revealed the presence of another 
conserved domain, termed the death domain (DD), necessary for apoptosis in response to 
agonistic Fas antibodies [8]. Death domains are protein modules containing six 
antiparallel, amphipathic alpha helices organized into a conserved overaIl fold, and are 
present in a subset of the TNFR superfamily [9]. In addition to TNF receptors, multiple 
cytosolic adaptor proteins also contain DDs and are recruited to Fas via homotypic 
interactions to initiate Fas signaling. 
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Fas death signaling 
While FasL-Fas interactions activate multiple and pleiotropic signaling cascades 
[10-12], the best characterized outcome of Fas signaling is apoptosis. Vpon activation by 
FasL or agonistic antibodies, Fas associates with the Fas associated death domain 
(FADD), a DD containing adaptor protein, which further recruits Caspase 8 and/or 
Caspase 10 to form the Death-Inducing Signaling Complex (DISC) [12]. Caspase 8 is 
activated within the DISC by autocatalytic c1eavage. Activated Caspase 8 proceeds to 
activate either Caspase 3 directly, as part of the extrinsic apoptosis pathway or indirectly, 
via mitochondrial destabilization, as part of the intrinsic pathway [13]. In the intrinsic 
pathway, c1eavage of the protein Bid by activated Caspase 8 results in destabilization of 
the mitochondrial membrane potential, and release of cytochrome cinto the cytosol [14]. 
Release of cytochrome c stimulates formation of the apoptosome, composed of Caspase 
9 and the apoptotic protease activating factor 1 (APAF1), which can c1eave and activate 
Caspase 3 [15]. Both pathways converge on activation of the executioner Caspase 3, 
resulting in cleavage of multiple cellular proteins, and activation of the Caspase-activated 
DNase (CAD), resulting in characteristic internuc1eosomal chromatin fragmentation and 
apoptosis [16]. 
Non-apoptotic Fas Signaling 
Cellular outcomes 
In addition to the better characterized apoptotic outcomes of Fas signaling, Fas 
engagement can also result in multiple cellular outcomes besides apoptosis, complicating 
the interpretation of many experiments. For instance, Fas signaling can induce both 
proliferation and apoptosis of fibroblast cells [17 ,18]. Intriguingly, although Fas 
engagement normally kills hepatocytes in the healthy liver, the outcome of Fas signaling 
is reversed after partial hepatectomy, where Fas stimulation accelerates liver regeneration 
[19]. Fas also induces hypertrophy of cardiomyocytes in vitro and in vivo [20]. In the 
nervous system, Fas engagement induces neurite outgrowth as well as neurite branching 
[21,22] and Fas deficient lpr mice exhibit increased susceptibility to Parkinson's disease 
[23] and delayed peripheral nerve regeneration [21]. Even in the immune system, where 
Fas mutants exhibit excessive lymphoproliferation due to apoptotic defects, Fas has been 
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documented to have non apoptotic effects. Fas engagement can induce secretion of pro 
inflammatory cytokines, such as Interleukin 1 (IL-l), from activated immune cells [24]. 
Stimulation of Fas with agonistic antibodies, which stimulate Fas signaling, can cause T 
and B lymphocytes to proliferate in culture [25,26]. This interesting ability of FasL, 
acting through Fas, to paradoxically cause both proliferation and apoptosis parallels other 
proteins of the TNF superfamily, many of which are also multifunctional [27]. 
Molecular mechanisms 
The non apoptotic effects of Fas signaling downstream of FasL imply the ability 
of Fas to activate other pathways, distinct from the classical apoptotic caspase cascade. 
Surprisingly, even sorne of the non-apoptotic Fas signaling pathways require caspase 
activation. Fas induced T cell proliferation is blocked by caspase inhibitors [28]. 
Interestingly, there is a growing body of work indicating that the caspases, key mediators 
of the cell death pathway, also regulate nonapoptotic cellular functions such as 
proliferation and differentiation [29]. 
Other non apoptotic effects of Fas require activation of signaling pathways 
distinct from the caspase cascade. Fas induced neurite outgrowth requires activation of 
the Extracellular-signal Regulated Kinase (ERK) Mitogen Activated Protein Kinase 
(MAPK) pathway [21], and Fas activation in fibroblasts triggers activation ofERK as 
weIl as nuclear factor KB (NF-KB) [30]. The ERK MAPK cascade is one of three MAPK 
phosphorylation cascades activated downstream of multiple growth factors, and is 
associated with growth and differentiation. NF-KB is a ubiquitous transcription factor 
that controls the expression of genes involved in inflammation, apoptosis, and cell cycle. 
NF-KB is activated by multiple stimuli which trigger the phosphorylation and subsequent 
degradation of its cytosolic inhibitor, I-KB [31]. The cytosolic Fas- associated death 
domain-Like interleukin Ibeta-converting enzyme)-Inhibitory Protein (FLIP), has been 
shown to mediate activation of both of these pathways downstream of Fas [32]. FLIP 
binds to the adaptor protein FADD, and acts as an inhibitor of apoptosis downstream of 
death receptors [33], and can instead activate other signaling pathways. Therefore, FLIP 
may be a key regulator of Fas non apoptotic versus apoptotic signaling. Rather than 
proliferate, FLIP-/- fibroblasts die in response to FasL [34]. The Fas Associated 
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Phosphatase (FAP-l) is another Fas interacting protein that can inhibit apoptosis [35], 
and alternatively activate signaling via NF-KB [36]. The outcome of Fas signaling may 
also be controlled by exposure of cells to growth factors, whose downstream effects can 
interfere with Fas induced DISC formation [37], and upregulate mitochondrial proteins 
which act as inhibitors of apoptosis [38]. 
PART II: Fas Ligand 
FasL: the mole cule 
Fas Ligand (FasL) is a 281 amino acid single pass transmembrane protein, first 
identified in a screen for cell surface proteins that bound to Fas. In 1993, it was 
discovered that a certain cellline, PC60-dlOS, was capable of killing Fas positive, but 
not Fas negative, target cells in co-culture experiments, implying the presence of a Fas 
"ligand" protein [39]. To identify the ligand, a Fas-IgG fusion protein was produced and 
used to sort high FasL expressing cells as a source for the creation of a cDNA library 
[40]. Plasmid DNA was then transfected into COS cells and plasmids were re-isolated 
from cells that bound to Fas-IgG in vitro. Sequences identified after multiple rounds of 
this type of panning, led to the identification of the Fas Ligand. FasL is a type II 
transmembrane protein, meaning the C terminus rather than the N terminus is presented 
extracellularly, and a member of the TNF superfamily. Membership in this family is 
based on homology within the extracellular domains of these molecules. Although there 
is a relatively low level of primary sequence homology (not exceeding 35%) amongst 
members of the TNF superfamily, they are predicted to have similar topology and exhibit 
a homotrimeric structure [41]. Mutagenic analyses of FasL indicate that the membrane 
proximal amino acids of the extracellular domain are responsible for this trimeric self 
association, while the extreme C terminal amino acids are required for Fas receptor 
binding [42]. The FasL extracellular domain also contains three sites ofN or asparagine 
linked glycosylation, which do not appear to be required for induction of apoptosis via 
Fas [42]. In addition to binding Fas, the FasL extracellular domain also binds to the 
secreted decoy receptor 3 protein, which blocks its activity as an apoptosis inducer via 
Fas [43,44]. Intracellularly, FasL contains a long, 80 amino acid cytoplasmic tail which 
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is distinct from the shorter intracellular tails of other TNF superfamily members. Within 
this intracellular tail are putative consensus sequences for phosphorylation by Casein 
Kinase 1 (CKl) and glycogen synthase kinase 3~ (GSK3~), as well as an extended region 
of very high proline content, capable of interacting with Src Homology 3 (SH3) and WW 
domain containing proteins [45,46]. 
FasL Expression and Function 
Immune cells 
FasL expression is best documented in the immune system, where it is thought to 
regulate the survival of T cells. Peripheral T cells initially undergo a clonaI expansion 
phase after exposure to antigen as the y proliferate in response to interleukin-2 (IL-2) 
[47]. Later however, these expanded cells are eventually eliminated by an apoptotic 
process called Activation Induced Cell Death (AICD) in order to terminate the immune 
response and maintain homeostasis. FasL expression is induced in T cells in vitro after 
stimulation of the T cell Receptor complex (TCR), and a soluble Fas-IgG fusion protein 
inhibits AICD [48-50]. Interestingly, IL-2, which initially upregulates FasL and 
promotes T cells proliferation, primes cells for death via FasL later in the immune 
response [51]. Due to the ability of single, isolated T cells to undergo AICD in response 
to TCR engagement, Fas and FasL have been proposed to be capable of interacting in a 
cell autonomous manner to indu ce cell "suicide" [49]. 
In contrast to the role for FasL in regulating the survival of peripheral T cens, the 
role for FasL in regulating deletion of unwanted T cells during their development and 
maturation in the thymus is more controversial. While sorne reports have indicated that 
FasL was involved in thymic deletion (negative selection) of autoreactive thymocytes 
[52], others have found that FasL was not involved [53]. These contradictory reports 
may perhaps be explained by the finding that FasL is involved in thymic deletion of T 
cells upon exposure to high levels but not low levels of antigen [54]. 
FasL is also thought to mediate the target cell killing activities of cytotoxic T 
lymphocytes (CTLs) and natural killer (NK) cens [55,56]. CTLs and NK cells are potent 
killers of tumorigenic and virally infected cens at least in part via the regulated secretion 
of the contents of specialized secretory lysosomes, which contain lytic proteins such as 
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perforin and granzyme [57]. There is evidence that FasL is localized to these secretory 
lysosomes in cells that contain these specialized organelles and that appearance of 
surface FasL in these cells correlates with their de granulation [58]. 
Immune phenotype of F as/F asL mutants 
Consistent with the role for Fas and FasL in the termination of immune 
responses, mice and humans with inactivating mutations in the FaslFasL system exhibit a 
dramatic immune phenotype. Lpr (lymphoproliferative) mice, which cannot efficiently 
transcribe Fas due to the insertion of a transposable DNA element into a gene intron, 
develop lymphadenopathy and are may display symptoms resembling a systemic lupus 
erythematosus-like autoimmune disease [59]. Similarly gld mice (generalized 
lymphoproliferative disease) also exhibit lymphadenopathy and autoimmune symptoms 
due to an inactivating missense mutation (Phenylalanine to Leucine) at the extreme 
carboxyl terminus of FasL [60]. In gld animaIs, FasL is expressed normally at the cell 
surface and is properly oligomerized, yet was reported to be incapable of killing Fas 
expressing cells [60,61]. The phenotype of FasL knockout animals, however, indicated 
a residual activity of the gld allele. FasC/- animaIs exhibit splenomegaly, and a more 
severe autoimmune phenotype compared to gld animaIs, with lymphocytic infiltration 
into multiple organs and death of greater than 50% of mice by 4 months of age [62]. A 
third mouse mutation in the Fas system, named lpl'g (lpr complementing gld), results in 
lymph node hyperplasia and high titers of autoantibodies [63]. The lprcg mutation results 
in local unfolding of the Fas death domain, such that the adaptor protein FADD can no 
longer bind to Fas [64]. 
In humans, mutations in the Fas/FasL system can result in Autoimmune 
LymphoProliferative Syndrome (ALPS; Canale Smite Syndrome). Children with ALPS 
develop lymphoid hyperplasia and autoimmunity reminiscent of lupus, and ALPS is a 
good ex ample of a disease where the animal models have been highly informative. The 
disease is segregated into subtypes, based on the functional results of the various 
mutations found in the disease. ALPS 0, caused by a Fas null mutation, parallels lpr 
mice; ALPS la, results primarily from intracellular Fas mutations, and parallels lprcg 
mice; while ALPS lb is caused by FasL mutations, similar to gld mice [65]. 
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Interestingly, mutations discovered in caspase 10 in ALPS II patients led to the 
identification of caspase 10 as a component of the Fas DISC during apoptotic signaling 
[66]. A table outlining the mutations in the various proteins along the Fas death pathway 
in ALPS has been reproduced from reference [65] below: 
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Fig. 1 Various ALPS Subtypes Related to Their Respective Mouse Mutations 
Within the Cell Death Pathway. 
New Abbreviations: TRAIL (TNF Related Apoptosis Inducing Ligand); DR (Death 
Receptor); CASP (Caspase); TRADD (TNF Receptor Associated Death Domain); TL1-A 
(TNF ligand-related molecule lA); SLE (Systemic Lupus Erythematosus) 
Expression of FasL in non-immune ceUs 
FasL is also expressed outside the immune system, in the nervous system [67-69], 
the reproductive system [70], the eye[71], and on various epithelia [72]. Many of the se 
tissues are considered to be "immune privileged," meaning that it is difficult to evoke 
immune responses in these anatomicallocations. More specifically, immune privileged 
sites are c1assically defined as anatornicallocations that are permissive of allograft or 
xenograft survival [73]. FasL has been hypothesized to be a mediator of immune 
privilege in these tissues, limiting the availability of such tissues to immune surveillance 
via the engagement of Fas on tissue infiltrating lymphocytes [67,68,71]. In a similar 
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fashion, the expression of FasL upon the surface of vascular endothelial cells may 
negatively regulate the extravasation of Fas expressing lymphocytes to sites of 
inflammation [74]. Inflammatory mediators, such as tumor necrosis factor alpha (TNF 
a), which upregulate adhesion molecules for lymphocyte extravasation [75] also 
downregulate FasL [74]. FasL is also expressed by various tumors [68,76,77], and their 
expression of FasL may be one of the multiple mechanisms used by neoplastie cells to 
escape immune rejection. 
Reports published in the journals Science and Nature in 1995 indicated that FasL 
may be a key regulator of immune privilege and initially piqued the interest of many 
transplant biology and tumor immunology researchers. Bellgrau et al. [78] reported that 
immunologieally mismatched grafts of wild type mouse testis survived, while testis 
grafts from gld miee were rapidly rejected. Griffith et al. [71] similarly reported that 
inflammatory cells entering the eye in response to viral infection underwent Fas 
dependent apoptosis in wild type animaIs, whereas gld animaIs exhibited inflammation 
and immune invasion of ocular tissue. Therefore FasL appeared to be required for 
immune privilege, but was it sufficient? A single report indicated that FasL expressing 
myoblasts surrounding pancreatie Langerhans cells allografts protected them from 
immune rejection [79]. However, multiple reports have indicated that ectopie FasL 
expression within transplanted tissues leads to premature rejection [80-82], inc1uding one 
report that used a very similar methodology [83]. These latter reports also documented 
massive infiltration of neutrophils to the graft site, associated with the rejection. 
Neutrophils may be attracted to sites of high FasL expression via Fas induced production 
of interleukin 1 (IL-l) [24] and/or IL-8 [84], two neutrophil chemoattractants. Studies of 
FasL expression in tumor cells and its role in "immune counterattack" paralleled the 
contradietory findings of transplant biologists. While sorne studies found that FasL 
expression increased tumor survival in vivo [85], others found that FasL expression in 
tu mors caused neutrophilic infiltration and destruction [86]. 
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Regulation of Fas Ligand 
Transcriptional Regulation of FasL 
As a protein with the capability of inducing apoptosis under certain conditions, 
the expression of FasL must be tightly controlled. Few cell types constitutively express 
FasL messenger RNA (mRNA) and transcription of FasL is often induced by external 
stimuli. In T cells, one such stimulus is activation of the TCR complex, which results in 
the expression of the FasL mRNA and precedes AICD [48]. Two sites in the FasL 
promoter region have been identified as nuclear factor of activated T cells (NF A T) 
transcription factor binding sites that are critical for optimal expression of FasL in 
activated T cells [87]. Other transcription factors, such as the early growth factor 
response (EGR) factors 1 and 3, bind adjacent regions within the FasL promoter and 
cooperate synergistically with NF AT in the induction of FasL transcription downstream 
ofT cell activation [88]. NF-KB has also been documented to participate in FasL 
induction during AICD [89]. 
Another stimulus for FasL expression is cellular "stress." Exposure of cultured 
cells to damaging stimuli, such as UV light, gamma rays, or certain toxic drugs, causes 
them to upregulate FasL expression and commit stress induced apoptosis. Induction of 
FasL expression in response to at least sorne stress stimuli is mediated by activation of 
the c-Jun N terminal Kinase (JNK; also known as stress activated protein kinase), another 
MAPK cascade distinct from ERK that is activated by cellular stress [90]. As its name 
implies, the kinase JNK phosphorylates the protein c-Jun, allowing it to translocate to the 
nucleus and activate transcription as part of the AP-1 complex. Formation of the AP-1 
complex upon the FasL promoter downstream of JNK activation mediates FasL 
induction in response to stress [91]. The transcription factor NF-KB has also been shown 
to participate in FasL expression in response to cellular stress induced by the cancer 
drugs etoposide and teniposide [92]. Growth factor withdrawal, another cellular stress, 
also stimulates FasL expression. Many growth factors bind receptors which facilitate the 
activation of the Akt protein kinase, which promotes cellular survival by phosphorylating 
and inhibiting the forkhead transcription al regulator-1 (FKHRL1) [93]. FKHRL1 binds 
to two response elements in the FasL promoter and facilitates its expression [93]. 
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Translational Regulation of FasL 
Little is known of the translation of the FasL mRNA, although it has been 
observed that levels of FasL mRNA do not necessarily correlate with levels of FasL 
protein expression [94]. One possible explanation for this observation could be 
regulation of FasL translation. In a recent paper, Xiao et al. [95] documented a dramatic 
augmentation in protein expression levels of various FasL intracellular tail deletion 
mutants in stable celllines compared to the wild type protein, despite equal expression of 
their respective mRNAs. These results are potentially suggestive of a negative 
translational regulatory element within the nucleotides encoding the FasL amino 
terminuslintracellular tail. This interpretation is complicated, however, by the 
subsequent finding that the se deletion mutants exhibit decreased cytotoxicity [96], and 
there are alternative explanations for differing protein levels, such as altered protein half 
life, which the authors did not investigate. Dramatic increases in radioactive methionine 
incorporation after very short (5 minute) labelings of cells expressing the deletion 
mutants compared to cells expressing the wild type protein, [95] nonetheless lend 
credibility to the translation hypothesis. This thesis utilizes the same intracellular tail 
deletion mutants as Xiao et al. for the analysis of protein interactions, and using a slightly 
different experimental system, reproduces the augmentation of FasL protein expression 
upon FasL n-terminal deletion (see Chapter 2, Fig. 1). 
Post-translational Regulation of FasL 
Another mechanism for the regulation of FasL expression and function is the 
shedding of its extracellular domain to generate a soluble FasL (sFasL), leaving behind a 
transmembrane and intracellular domain "stump." Other TNF family members, such as 
TNF, are also cleaved in a similar fashion [97]. Extracellular domain shedding of FasL 
is achieved by the action of metalloproteinase enzymes [98,99]. sFasL has 
approximately 1000 fold less killing activity than the membrane bound form of FasL 
[100], although in certain tissues sFasL can bind to the extracellular matrix protein 
fibronectin to restore its cytotoxicity [101]. Little is known of the fate of the remaining 
cleavage product containing the FasL intracellular domain, although there is evidence 
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that the analogous cleavage product of TNF enters the nucleus and influences gene 
expression [102]. The A Disintegrin And Metalloproteinase subfamily member 10 
(ADAMlO) has recently been identified as an enzyme capable of generating this sFasL in 
vivo [103], and Matrix Metalloproteinase 7 (MMP7) has also been demonstrated to 
cleave FasL in vitro [104]. Interestingly, MMP 7 expression is negatively correlated 
with survival of colorectal cancer patients [105], perhaps due to its ability to cleave FasL 
and downregulate apoptosis [106]. 
FasL has also recently been documented to be post-translationally regulated by its 
entry into lipid rafts. Lipid rafts are cholesterol, sphingolipid and saturated fatty acid rich 
microdomains within the celI membrane which are thought to concentrate proteins 
involved in signal transduction [107]. Two recent studies provide evidence that FasL 
enters these membrane microdomains and that disruption of these microdomains strongly 
decreases the apoptosis inducing activity of FasL [108,109]. Although the two studies 
differ somewhat in their results, both studies also indicate that regions of the FasL 
intracellular domain, particularly the proline rich region, are necessary for membrane raft 
localization. 
The localization of FasL to the cell surface, where it is readily available to bind 
Fas and exert its biological effects, is also a regulated process. Multiple reports have 
documented significant intracellular retention of FasL [58,95,110-113]. In a subset of 
hematopoietic cells that contain secretory lysosomes, such as cytotoxic T lymphocytes 
and mast celIs, FasL is predominantly intracellular and colocalizes with lysosomal 
markers, while cells lacking the se specialized organelles express cell surface FasL with 
variable levels of intracellular retenti on depending on the cell type [58,95,113]. The 
FasL intracellular domain (ICD) is likely sufficient for its intracellular retention, as 
fusion of the FasL ICD to the cell surface expressed CD69 protein results in intracellular 
retenti on of the fusion prote in [58]. More specificalIy, deletion of the proline rich region 
of the FasL ICD results in surface expression, rather than intracellular retenti on of FasL 
in cells with secretory lysosomes [113]. In cytotoxic T lymphocytes, stimulation of the 
TCR results in regulated exocytosis from FasL containing secretory lysosomes [114]. 
Secreted microvesicles bearing FasL have been isolated, and are thought to derive from 
these secretory lysosomes [115-117]. In contrast to cells which contain secretory 
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lysosomes, little is known of the factors which regulate cell surface expression of FasL in 
other cell types. 
FasL Reverse Signaling 
There is significant evidence that in addition to initiating signaling through Fas, 
FasL can also transduce "reverse signaIs," and thus participate in bidirectional signaling. 
This phenomenon is documented for several members of the TNF superfamily, which 
transduce many critical and diverse signaIs in normal immune function, such as cellular 
proliferation, cytokine and growth factor secretion, and immunoglobin class switching 
[118]. Two papers published in 1998 were the first to document the effects of FasL 
reverse signaling. Desbarats et al. [119] reported that stimulation of primary CD4+ T 
cells with a Fas-Irnmunoglobin fusion protein inhibited their proliferation and caused 
them to enter cell cycle arrest and later cell death. By documenting the same effect in 
Fas, but not FasL mutant mice, the authors demonstrated cell cycle arrest occurred via 
FasL reverse signaling and could not be explained by the blocking of Fas/FasL 
interactions. Interestingly, Suzuki et al. [120] found that stimulation of CD8+ T cell 
clones in a similar fashion augmented their proliferation. A follow up study later 
demonstrated, that although CD4+ T cells can also be positively stimulated via FasL 
reverse signaling, a concomitant upregulation of surface FasL causes CD4+ T cells to 
later undergo apoptosis, whereas CD8+ T cells are relatively insensitive to Fas induced 
death [121]. Therefore, differences in sensitivity to Fas induced apoptosis between the 
two cell types may explain the seemingly contradictory data of the two above 
experiments. 
Cross-linking of endogenous Sertoli cell FasL induces activation of the ERK 
cascade and subsequent activation of cytosolic phospholipase A2 (cPLA2) [70]. 
Inhibition of either pathway results in decreased levels of sFasL in cultured cell 
supernatants [70], suggesting that FasL reverse signaling in Sertoli cells may act to 
regulate the production of sFasL. In T cells, cross linking of an overexpressed FasL 
intracellular domain also results in ERK activation, as well as activation of the 
phosphatidyl inostiol 3' kinase (PI3K) protein kinase B (PKB) pathway [122]. The Src 
homology 3 (SH3) domain containing adaptor proteins Growth Receptor Bound 2 (Grb2) 
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and p85, important for triggering both of these pathways, are recruited to the FasL ICD, 
in response to Fas stimulation [122]. SH3 domains bind to proline rich sequences [46], 
and are therefore likely recruited to the proline rich region of the FasL ICD. Cross 
linking of this FasL intracellular tail construct also activates reporter plasmids for the 
transcription factors NF AT , AP-l, as weIl as transcription of the cytokines Interferon y 
and IL-2 [122]. Inhibition ofERK activation abrogates cytokine production induced by 
FasL reverse signaling [122], suggesting that this pathway may underlie FasL reverse 
signaling induced T cell proliferation. 
Interestingly, TNF, the most closely related member of the TNFSF, can also 
trigger the ERK cascade via reverse signaling [123]. Unlike Fas L, TNF does not contain 
a large proline rich region. The TNF ICD contains a highly conserved SXXS sequence, 
which is a consensus target sequence for phosphorylation by Casein Kinase 1 (CKl). 
This sequence is present in many members of the TNFSF and has been documented to 
change phosphorylation state during TNF reverse signaling [124]. Changes in Serine 
phosphorylation have also been documented during FasL reverse signaling as weIl [122]. 
Collectively, these data imply that the CKI consensus sequence may be sufficient for 
FasL reverse signaling induced ERK activation, as TNF is capable of activating this 
cascade despite the lack of a proline rich domain. To date however, a convincing 
molecular mechanism linking TNFSF member serine phosphorylation to ERK activation 
has not been defined. TNFSF reverse signaling has important clinical implications, as 
antibodies designed to inhibit TNF activity in autoimmune diseases such as Rheumatoid 
Arthritis and Crohn's disease are currently being evaluated in clinical trials. In addition 
to blocking engagement of TNFR signaling, these antibodies can also sufficiently cross 
link TNF to activate TNF reverse signaling [125], and may lead to unexpected clinical 
outcomes by modulating cytokine production and immune function [125,126]. 
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FasL Interacting Proteins 
Multiple proteins capable of binding to FasL in T cells have been identified. A 
group led by O. Janssen in Germany conducted a screen in 2002 for Glutathione S 
Transferase (GST) fusion proteins capable of co-precipitating FasL from FasL 
overexpressing KFL-9 cells [45,46]. Many of the proteins identified contain SR3 or 
WW domains, which are capable of binding to proline rich sequences. Of the proteins 
identified, a surprising number of proteins modulate FasL localization, and several may 
participate in FasL reverse signaling. As this thesis focuses on FasL interacting proteins, 
the most relevant findings published to date for each interacting protein will be outlined 
below. 
Grb2 
Grb2 is an adaptor protein containing one Src homology 2 (SR2) and two SR3 
domains. Its SR2 domain allows it to bind to phosphotyrosine residues found in receptor 
tyrosine kinases, such as the Epidermal Growth Factor Receptor (EGFR) [127]. Grb2 
binding recruits the guanosine triphosphate (GTP) exhange protein Son of Sevenless 
(SOS) to the membrane via its SR3 domain [128]. SOS can then complex with the Ras 
GTPase protein and activate it by exchanging Ras bound guanosine diphosphate (GDP) 
for GTP [128]. Activated Ras can then activate the protein kinase Raf, which can further 
activate a kinase cascade by phosphorylating the Mitogen activated ERK kinase (MEK), 
which can phosphorylate ERK [129]. Phosphorylated ERK enters the nucleus and can 
affect gene transcription by phosphorylating transcription factors. 
Grb2 was originally identified as a protein co-precipitated with a GST -FasL ICD 
fusion prote in in T cells [45]. Based on its ability to function as an adaptor protein for 
ERK activation downstream of receptor tyrosine kinases, Grb2 has been hypothesized to 
mediate FasL reverse signaling induced ERK activation. In this thesis, evidence is 
presented that in addition to its potential role in FasL reverse signaling, Grb2 may also 
act as a regulator of FasL localization (see Chapter 3). 
P85 Subunit of PI3K 
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The p85 subunit of the phosphatidyl inositol3'phosphate kinase (PI3K) is an SH3 
do main containing adaptor protein for the enzyrnaticaIly active 110 kilo dalton subunit of 
PI3K. As its name suggests, PI3K phosphorylates the 3' hydroxyl group ofthe 
phosphatidyl inositol phospholipid within the ceIl membrane. Local increases in 3' 
inositol phosphates upon the inner leaflet of the cell membrane recruît Protein kinase B 
(PKB) to the membrane where it becomes activated [130]. Activated PKB is associated 
with cell cycle progression and cellular growth. 
The p85 subunit ofPI3K was identified as a GST -SH3 do main fusion protein 
capable ofco-precipitating FasL [46]. Phosphorylation ofPKB on Serine 473, a key 
residue for enzyme activation, has been documented downstream of cells treated with a 
soluble Fas Irnrnunoglobin fusion protein [122]. Recruitment ofp85 to FasL has 
therefore been hypothesized to participate in FasL reverse signaling induced activation of 
the PI3K1PKB pathway. 
Sre Farnily Tyrosine Kinases 
Mulitple tyrosine kinases ofthe Src family have been documented to interact with 
FasL [46,131,132]. These kinases aIl contain SH3 domains, and GST-SH3 do main 
fusion proteins derived from the Fyn, Lyn and Fgr SH3 do mains are capable of co-
precipîtating FasL in vitro [46,131]. Ofthese proteins, Fgr has been demonstrated to 
phosphorylate tyrosine residues within the FasL intracellular tail [131]. To date, it is 
unclear ifFasL tyrosine phosphorylation is necessary for FasL reverse signaling. 
Tyrosine mutated FasL is found less abundantly within the multivesicular bodies of 
secretory lysosomes in cell types that contain this organelle, suggesting that tyrosine 
phosphorylation of the FasL ICD may modulate the sorting ofFasL [131]. 
PA CSIN proteins 
The Protein kinase c And Casein kinase Substrate in N eurons (P AC SIN) proteins, 
also known as syndapins, are a family ofthree SH3 do main containing proteins, which 
bind to FasL [45,133]. PACSIN 1 is expressed primarily in neural tissues, while 
PACSINs 2 & 3 are expressed more ubiquitously [134]. PACSIN proteins each contain a 
coiled coil (CC) oligomerization domain, as well as several NPF motifs, which bind to 
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Epsin Homology (EH) domain containing proteins, involved in the regulation of 
endocytosis [134]. P ACSlN proteins bind to multiple cellular proteins in addition to 
FasL. PACSINs bind to the GTPase dynamin, which controls the final fission step of 
vesicle formation [l35]. PACSINs also bind to the Wiskott Aldrich Syndrome Protein 
(W ASP), a potent activator of actin polymerization [l36]. Based on these two protein 
interactions, P ACSIN proteins have been hypothesized to couple vesicle formation with 
the actin cytoskeleton, perhaps in such a way that the cytoskeleton aids in fission or 
'pinching off' of vesicles from the cell surface or organellar membranes [l34]. Co-
transfection of P ACSIN proteins with FasL results in relocation of FasL from the cell 
membrane to intracellular vesicular structures in non hematopoietic cells, whereas 
PACSIN proteins colocalize with lysosomal FasL in hematopoietic celIs [l33]. 
Interestingly, PACSIN3 protein can also bind to members of the ADAM family of 
metalloproteinases and upregulate extracellular domain shedding of the heparin-binding 
epidermal growth factor-like growth factor [l37]. As ADAM family members are 
implicated in FasL extracellular domain cleavage, it is interesting to speculate that 
PACSIN3 may regulate this process by linking members of the ADAM family to the 
FasL intracellular tail. 
PSTPIP 
The Proline, Serine and Threonine Phosphatase-Interacting Protein (PSTPIP) was 
initially identified as a FasL interacting protein in a yeast two hybrid screen [l38]. 
PSTPIP contains an SH3 domain, which interacts with the FasL proline rich region, and 
a coiled coil domain, which allows it to interact with the Protein Tyrosine Phosphatase-
PEST (PTP-PEST). PSTPIP recruits PTP-PEST to the FasL intracellular domain [l38], 
and may influence the phosphorylation state of the FasL intracellular domain. 
Overexpression of PSTPIP results in decreased cell surface FasL and intracellular 
retention in a proline rich domain dependent manner [l38]. PSTPIP may therefore 
participate in both the trafficking and reverse signaling of FasL. 
Nck 
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Nck is an adaptor protein containing three SH3 domains and one SH2 domain. In T 
ceIls, Nck binds to both the WASP protein [139] and the T Cell Receptor (TCR) complex 
[140], and recruits WASP to the TCR to facilitate local changes in actin polymerization 
in response to TCR engagement by peptide/major histocompatibility complexes (MHC) 
on antigen presenting cells (APCs) [141]. WASP facilitated actin polymerization at sites 
of TCR-MHC contact plays a critical role in formation of an immunological synapse, 
allowing the directed secretion of cytokines to sites of cell-cell contact [142]. Nck binds 
to the proline rich region of the FasL ICD and partially colocalizes with FasL and 
lysosomal markers at sites of cell-cell contact in cytotoxic T lymphocytes (CTLs) [143]. 
Treatment of cells with a short interfering RNA (siRNA) targeting Nck reduces 
localization of FasL to sites of cell-cell contact [143]. Nck may therefore act as a 
regulator of FasL secretion from secretory lysosomes to sites of cell-cell contact, and 
thereby participate in CTL target cell killing. 
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OBJECTIVES: 
Fas Ligand has been extensively studied as an inducer of apoptosis, particularly 
in the immune system. Both Fas and FasL are also expressed in the cells of the nervous 
system, inc1uding glial cells, and are upregulated after in jury [69]. Recent data document 
prominent non-apoptotic roles for nervous system Fas in the regulation of neurite 
outgrowth and neurite branching [21,22]. Mice expressing hypofunctional Fas and FasL 
exhibit delayed peripheral nerve regeneration [21], suggesting that FasL, acting either 
through Fas forward or FasL reverse signaling, may play a key role in the injured 
nervous system. Schwann cells, glial cells of the peripheral nervous system, are essential 
for peripheral nerve regeneration, contribute to the extensive tissue remodeling that 
occurs during healing, and also express FasL after peripheral nerve injury [69]. 
The primary objective of this thesis is to investigate the spectrum of FasL 
interacting proteins within nervous system Schwann cells. By regulating FasL 
localization, as weIl as potentially participating in FasL reverse signaling, FasL 
interacting proteins may participate in or modulate peripheral nerve regeneration. The 
secondary objective of this thesis is to elucidate to the greatest extent possible, the 
consequences of novel FasL-protein interactions in order to shed insight into the 
complicated cellular biology of FasL. 
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Chapter 2 
A Proteomic Screen Reveals Novel Fas 
Ligand Interacting Proteins within 
Nervous System Schwann cells 
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ABSTRACT: 
Fas Ligand (FasL) binds Fas (CD95) to induce apoptosis or activate other 
signaling pathways. In addition, FasL transduces bidirectionai or 'reverse signaIs.' The 
intracellular domain of FasL contains consensus sequences for phosphorylation and an 
extended proline rich region, which regulate its surface expression. Here, we used a 
proteomics approach to identify novel FasL interacting proteins in Schwann cells to 
investigate signaling through and trafficking of this protein in the nervous system. We 
identified two novel FasL interacting proteins, sorting nexin 18 and adaptin ~, as well as 
two proteins previously identified as FasL interacting proteins in T cells, PACSIN2 and 
PACSIN3. These proteins are all associated with endocytosis and trafficking, 
highlighting the tight regulation of cell surface expression of FasL in the nervous system. 
Keywords: Fas Ligand, protein interactions, Src homology 3 domain, Schwann cell 
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INTRODUCTION: 
Fas Ligand (FasL, CD95L, CD 178), a member of the tumor necrosis factor (TNF) 
superfamily, is a type II, homotrimeric protein with cell surface and secreted isoforms. 
FasL is inducibly expressed by cells of the immune system upon activation and in the 
nervous system after injury, and is constitutively expressed in "immune privileged" 
tissues, such as the eye and reproductive systems [70,71,144]. Traditionally, FasL has 
been viewed exclusively as a ligand for the Fas receptor, stimulating formation of a death 
inducing signaling complex (DISC) and activation of a caspase cascade, ultimately 
culminating in apoptosis [10,145]. The apoptotic effector function of FasL is particularly 
weIl documented in the immune system, where FasL is an effector of activation induced 
lymphocyte cell death (AICD), and oftarget cell killing by cytotoxic T lymphocytes [47-
50,146]. Consistent with this, mice and humans with mutations in the FaslFasL system 
exhibit massive lymphoproliferation and are susceptible to developing autoimmunity 
[147,148]. In addition to the effector function of FasL as a ligand for Fas, increasing 
evidence has suggested that FasL and other membrane-bound TNF superfamily ligands 
can also transduce "reverse signaIs" and thus participate in bidirectional signaling. This 
phenomenon is now documented for several members of the TNF superfamily, which 
transduce many critical and diverse signaIs in normal immune function, such as cellular 
proliferation, cytokine and growth factor secretion, and immunoglobin class switching 
[118,126]. 
The FasL intracellular domain (ICD) contains a modular architecture consistent 
with its role as a signal transducing molecule. It contains a 26 amino acid proline rich 
region which interacts with multiple Src homology 3 (SH3) and WW domain containing 
proteins in T cells, including several members of the Src tyrosine kinase family [45,46]. 
In T cells, stimulation of FasL with agonistic antibodies or Fas fusion proteins increases 
its association with select SR3 do main containing proteins and resuIts in activation of the 
extracellular-signal regulated kinase (ERK) mitogen activated protein kinase (MAPK) 
pathway [70,122]. In addition to its potential role in signal transduction, the FasL proline 
rich region has also been implicated in sorting of the mole cule to different cellular 
compartments [113], which may be important for regulating both FasL effector and 
reverse signaling activities. The FasL ICD also contains a conserved, cytosolic casein 
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kinase 1 (CKI) motif (SXXS) that has been implicated in reverse signaling in other TNF 
family members [118,124]. Recently Sun et al. have documented changes in FasL serine 
phosphorylation fonowing treatment of cultured cens with a Fas fusion protein [122]. 
We and others have previously shown that FasL can influence the proliferation of 
T cens in the immune system via reverse signaling [70,119,120,122]. However, reverse 
signaling in TNF superfamily members has never been studied in the nervous system. 
FasL expression is induced on nervous system glial cens, inc1uding Schwann cens, 
following in jury [69]. Fas is also expressed in the nervous system and is upregulated 
after in jury [69], suggesting that Fas/FasL interactions, inc1uding FasL reverse signaling, 
may play a role in the injured nervous system. We have found that expression of Fas and 
FasL influenced peripheral nerve regeneration after crush injury [21] (and unpublished 
data). 
Here we used a proteomic approach to identify novel FasL interacting proteins in 
Schwann cells, the glial cells of the peripheral nervous system, to gain insight into 
mechanisms ofreverse signaling and trafficking of FasL in the nervous system. Using 
liquid chromatography-tandem mass spectrometry (LC-MSMS) for identification of 
FasL co-immunoprecipitating proteins, we identified Sorting Nexin 18 (SNXI8), adaptin 
13, Protein Kinase C and Casein Kinase Substrate in Neurons 2 (PACSIN2), and 
P ACSIN3 as FasL interacting proteins. The binding of FasL to multiple proteins 
implicated in trafficking suggests tight regulation of the reverse signaling and effector 
functions of FasL within the nervous system. 
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MATERIALS AND METHODS: 
Cells: 
Mouse Schwann cells were isolated from sciatic nerves of neonatal (P 1 to P3) 
C3HIHeJ mice. Mouse nerves were digested in collagenase (Sigma-Aldrich, Oakville, 
ON) then in trypsin / DNase (Worthington Biochemicals, Lakewood, NJ). The resulting 
cell suspensions were grown ovemight in DMEM supplemented with 10% fetal calf 
serum (FCS, Hyclone, Mississauga, ON), 100U/ml Penicillin and 100""glml 
Streptomycin (Gibco, Burlington, ON), and O.lmM non-essential amino acids (Gibco, 
Burlington, ON), then with 10 ""M cytosine-B-D-arabinofuranoside (Ara-C, Sigma-
Aldrich, Oakville, ON) for 48 hours. Confluent cultures of Schwann cells were treated 
with anti-mouse Thy1.2 (CD90.2) antibody containing supematant derived from the HO-
13-4 hybridoma (obtained from the American Type Culture Collection) and rabbit 
LowTox™ complement (Cedarlane, Burlington, ON) to remove residual fibroblasts. To 
verify the purity of the cultures, cells were examined using flow cytometry as follows: 
Cells were trypsinized from cell culture plates, then pelleted, and resuspended in PBS + 
2% fetal calf serum (FCS). Cells were then either permeabilized and stained using the 
Cytofix/Cytoperm™ fixation/permeabilization solution kit (BD Biosciences, 
Mississauga, ON) according to the manufacturer' s recommendations or stained in PBS + 
2% FCS for surface markers. Stainings were performed on ice for 25 minutes with the 
indicated primary antibodies or isotype control antibodies. After two wash cycles in PBS 
+ 2% FCS, or the provided PermlWash buffer, all samples were then stained with 
phycoerythrin conjugated anti mou se secondary antibodies (Groovy Blue Genes Biotech 
Ltd., Vineland, ON). Cells were washed twice more in PBS + 2% FCS or Perm/Wash 
buffer and analyzed using a FACSAria™ cell analyzer (BD Biosciences, Mississauga, 
ON). 
Construction of FasL deletion mutants: 
FasL deletion mutants, HuFasL~2-33-FLAG and HuFasL~2-70-FLAG, were 
created using wildtype, human FasL cDNA (Open Biosystems, Huntsville, AL) as a 
template to produce PCR products missing base pairs corresponding to N-terminal amino 
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acids 2-33 and 2-70, respectively, but still containing the initiator methionine (AUG) 
base pairs. The huFasL and huFasL62-33 coding sequences were PCR amplified using 
forward primers 5' CACCTGCAGCCATGCAGC-3' and 5'-
GGGCTGCAGCCATGACCTCTGTGCCC AGAAGGC-3' respectively, paired with the 
reverse 5'-CTCTTAAAGCTTATATAAGC CG-3' primer and PFUltra™ DNA 
polymerase (Stratagene, La Jolla, CA). The reactions were carried out for 20 cycles in 
lxPCR buffer, 0.8""M each primer, 250 ""M each dideoxynucleotide triphosphate 
(dNTP), and 2.5rnM MgCh, usingO.5 ng/""l template DNA as starting material. The 
resulting PCR products, as well as the vector pCMV-Tag4A, (Stratagene, La Jolla, CA) 
were then digested with Pst! (lnvitrogen, Burlington, ON) and HindIII (New England 
Biolabs, Ipswich, MA) according to the manufacturer's recommendations to generate 
complementary overhanging base pairs for cloning. The two digestion products were 
then ligated together using T4 DNA Ligase (Invitrogen, Budington, ON), using a 10 fold 
molar ratio of insert to vector, and transformed into chemically competent DH5a 
Escherichia coli. Ligation into pCMV -Tag4A facilitated the creation of C-terminal 
FLAG tagged proteins, due to the presence of this epitope in the vector, before the 
translational stop site. HuFasL-FLAG and huFasL62-33-FLAG were then excised with 
Pst! and Acc651 (Fermentas, Budington, ON), and the overhanging base pairs were 
"filled in" using the Klenow fragment (Invitrogen, Burlington, ON) of DNA polymerase 
1 according to the manufacturer' s recommendations. The resulting products were then 
ligated into the pIRES2-EGFP (Clontech, Mountainview, CA) Smal (New England 
Biolabs, Ipswich, MA) site using a 5 fold molar excess of insert to vector. 
HuFasL62-70-FLAG was created by PCR amplification with primers 5'-
GGGCTGCAGCCATGCTGAAGAAG AGAGGGAACCACAGC-3' (forward) and 5'-
CTACTTATCGTCGTCATCCTTG-3' (reverse) using huFasLFLAG as a template and 
the reaction conditions outlined above. As the PCR process does not leave terminal 
phosphates necessary for ligation, the resulting PCR product was phosphorylated with T4 
Polynucleotide Kinase (Gibco, Burlington, ON) according to the manufacturer's 
recommendations before being ligated into the pIRES2-EGFP Smal site. AlI vectors 
were full y sequenced before transfecting into cells to ensure the absence of 
mutations/frameshifts created during PCR amplification. 
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Creation of Stably transfected celllines: 
Mouse Schwann cells were transfected with huFasL-FLAG, huFasLLU-33-FLAG, 
huFasLf12-70-FLAG, or empty pIRES2-EGFP vector as a control using Lipofectamine 
2000™ (lnvitrogen, Burlington, ON) according to the manufacturer's recommendations. 
Fort Y eight hours after transfection, cells were trypsinized and GFP positive cells were 
single cell sorted into 96 well plates using a FACSAria™ fluorescence activated cell 
sorter (BD Biosciences, Mississauga, ON). Cells were expanded in DMEM with 10% 
FCS, O.lmM non essential amino acids (Gibco, Burlington, ON), lmM sodium pyruvate 
(Gibco, Burlington, ON) and 400 [lg/ml G4l8 (Wisent Bioproducts, St. Bruno, QC). 
Clones were then screened for expression of FasL constructs and GFP by 
immunoblotting cellular lysat~s with FasL and GFP antibodies. 
RNA isolation and RT -PCR: 
RNA extraction was performed on 2 x 105 cells using the ChargeSwitch total 
RNA kit (Invitrogen, Burlington, ON) according to the manufacturers instructions. RNA 
was quantified using the Quant-iT Ribogreen RNA assay kit (Invitrogen, Burlington, 
ON) according to the manufacturers protocol. Prior to reverse transcription, 40j.1g total 
RNA was denatured at 65°C for 5 min., then placed on ice. Reverse transcription (RT) 
reactions used a final volume of 20j.1L and contained 5J.1M random decamers (Ambion, 
Austin, TX), 0.5mM each dNTP, lOU RNA guard (GE Healthcare, Piscataway, NJ), IX 
Sensicript RT buffer (Qiagen, Mississauga, ON) and 4U Sensicript reverse transcriptase 
(Qiagen, Mississauga, ON). RT reactions were incubated 60 min., at 37°C. Primers for 
PCR amplification were as follows: l8S rRNA sense: 
5'TGAGAAACGGCT ACCACATCC3', l8S rRNA antisense: 
5'TCGCTCTGGTCCGTCTTGC3' , FasL sense: 
5 'CTGGTTGCCTTGGTAGGATTGGG3 , ,FasL antisense: 
5' GGACCTTGAGTTGGACTTGCCTG3 , , eGFP sense: 
5' GCCACAAGTTCAGCGTGCTCG3 , , eGFP antisense: 
5'TCTTCTGCTTGTCGGCCATGATAT3' (Invitrogen, Burlington, ON). PCR 
reactions were performed in a 25j.1L volume and contained 2j.1L cDNA, O.4j.1M each 
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primer, 0.2mM each dNTP (GE healthcare, Piscatatway, NJ), IX Hotstartaq PCR buffer 
(Qiagen, Mississauga, ON), and lU Hotstartaq (Qiagen, Mississauga, ON). Cyc1ing was 
performed by Techne Touchgene Gradient (Burlington, NJ) thermocyc1er as follows: 
18S rRNA: 15 min. at 95°C, cyc1ed 13X 60 s. at 94°C, 40 s. at 66.2°C, 30s. at 72°C, then 
final elongation 10 min. at 72°C. eGFP and FasL: 15 min. at 95°C, cyc1ed 25X 60 s. at 
94°C, 20 s. at 65.2°C, 40s. at 72°C, then final elongation 10 min. at 72°C. PCR products 
were visualized on 1.2% agarose gel (Invitrogen, Burlington, ON). 
Immunoprecipitation (IP) and Immunoblotting: 
For immunoprecipitation, cells were washed once in phosphate-buffered saline 
(PBS) and lysed in buffer containing 0.5% Nonidet P-40 (Bioshop Canada, Burlington, 
ON), 25mM HEPES pH 7.4,115 mM potassium acetate, 5mM magne sium chloride, 
1mM sodium orthovanadate (All from Sigma-Aldrich, Oak:ville, ON), and Complete 
Mini™ protease inhibitor tablet (Roche Diagnostics, Laval, QC). Lysates remained on 
ice for 15 minutes before centrifugation at 15,000 rpm for 10 minutes at 4°C. 
Supernatants were then prec1eared against unconjugated Sepharose 4B (Sigma-Aldrich, 
Oak:ville, ON) for 1.5 hours at 4°C. Sepharose beads were then pelleted, and prec1eared 
supernatants were incubated for at least 2 hours at 4°C with anti-FLAG or isotype control 
antibodies (Sigma-Aldrich, Oakville, ON) covalently cross-linked to Protein G-
Sepharose (GE Healthcare, Piscataway, NJ) using dimethyl pimelimidate (Sigma-
Aldrich, Oak:ville, ON). The beads were then pelleted, washed thrice in cold lysis buffer, 
boiled in Laemli buffer containing j3-mercaptoethanol, and electrophoresed on SDS 
polyacrylamide gels. SDS gels were then either transferred to polyvinylidene difluoride 
(PVDF) membranes (BioRad Canada, Mississauga, ON) and subjected to 
immunoblotting or stained with colloidal Coomassie blue (Invitrogen, Burlington, ON) 
followed by tandem mass spectrometry of unique gel bands. Gels transferred to PVDF 
membranes were blocked overnight at 4°C in 5% non-fat dry milk powder (w/v) in Tris-
buffered saline/O. 1 % Tween 20 (TBST, Fisher Scientific, Ottawa, ON) and blotted with 
the indicated primary and horseradish peroxidase (HRP) conjugated secondary antibodies 
diluted in blocking buffer and TBST respectively. Bands were visualized using ECL 
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plus reagents (GE Healthcare, Piscataway, NJ) and film from Molecular Technologies 
Inc. (Phillipsburg, NJ). 
Mass Spectrometry of Unique Gel Bands: 
Coomassie stained gel bands, detected in FLAG IP's but not in isotype control IP's, were 
excised and minced manually with a scalpel, washed with water and dehydrated in 
acetonitrile (Sigma-Aldrich, Oakville, ON). The corresponding gel area in the isotype 
controllane was also excised for mass spectrometric analysis to separate legitimate 
interacting proteins from those highly prevalent at the same molecular weight. Gel 
pieces were then spun down and dried using a vacuum centrifuge, fo llowed by reduction 
in 10 mM dithiotreitol/0.1 M ammonium bicarbonate (Sigma-Aldrich, Oakville, ON) for 
30 minutes at 56°C. Proteins were then alkylated in 55 mM iodoacetamide (Sigma-
Aldrich, Oakville, ON)/O.l M ammonium bicarbonate for 20 min at room temperature in 
the dark, followed by extensive washing in 1: 1 (v/v) O.lM ammonium 
bicarbonate/acetonitrile to remove residual Coomassie stain. After dehydration in 100% 
acetonitrile and vacuum drying, as above, gel particles were rehydrated in 50 mM 
ammonium bicarbonate, 5 mM calcium chloride (Sigma-Aldrich, Oakville, ON) and 
12.5 ng/J.lI oftrypsin (Promega Corp., Madison, WI) and digested overnight at 37°C. 
Peptides remaining in the gel were then extracted twice in 1: 1 (v/v) 25 mM ammonium 
bicarbonate/acetonitrile and 1: 1 (v/v) 5% formic acidlacetonitrile, respectively. 
Extracted samples were then pooled and dried using a vacuum centrifuge for mass 
spectrometryat the Institute for Research in Immunology and Cancer (IRlC) proteomic 
center at the University of Montréal. The dried peptides were resuspended in 5 ulofO.2 
% formic acid and injected on a NanoACQUITY HPLC system (Waters Limitée, 
Lachine QC). Peptides were fIfst trapped by an home-made reversed phase C18 
precolumn (300 J.lm internaI diameter x 5 mm length) and subsequently separated on an 
home-made C18 analytical column (150 J.lm internaI diameter x 10 cm, particle size 3 
J.lm). NanoLC separation was achieved using a 56-min linear gradient from 5% to 60 % 
aqueous acetonitri1e (0.2 % FA) at a flow rate of600 nl/min. Mass spectrometrie 
acquisitions in the MS/MS mode were performed on a Q-TOF Premier instrument 
(Waters Limitée, Lachine QC). Database searches were performed against the NCBI 
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non-redundant protein database using Mascot software (http://www.matrixscience.com). 
We used the following criteria to define potentially valid protein hits (Table 1): protein 
hits had to be supported by at least 3 peptides and have a predicted molecular weight 
within ~ 10 kDa of the excised gel band. Proteins with peptide hits present in the isotype 
background band were excluded from further analysis, as weIl as hits for antibody 
fragments, trypsin and/or other highly prevalent cellular proteins known to non-
specifically precipitate in IP experiments. 
Antibodies 
For immunoprecipitation, monoclonal anti-FLAG M2, or mouse IgG 1 control (Sigma-
Aldrich, Oakville, ON) were used. Anti-FasL G247.4 or anti-adaptin 13 (both BD 
Biosciences, Mississauga, ON) were used for the detection of immunoprecipitated 
proteins in western blots. EGFP was detected using clone JL-8 (Clontech, Mountain 
View, CA). For the detection of SNX18, anti-SNX18 antisera were generated by 
immunizing rabbits with a KLH-conjugated GFKKEYQKVGQSFR peptide (500~g) in 
Freund's Complete Adjuvant and boosting two times with peptide (100~g) in Freund's 
Incomplete Adjuvant. For flow cytometric detection, anti-SlOO (Chemicon, Temecula, 
CA), anti-GFAP, or anti-Thyl.2-PE (both BD Biosciences, Mississauga, ON) were used 
and compared to isotype control antibodies mouse IgG2a (BD Biosciences, Mississauga, 
ON), mou se IgG2b (Sigma-Aldrich, Oakville, ON), and rat IgG2a-PE (BD Biosciences, 
Mississauga, ON), respectively. Non-Fluor chrome linked primary antibodies were 
detected with phycoerythrin conjugated anti mouse secondary antibodies (Groovy Blue 
Genes Biotech Ltd., Vineland, ON). 
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RESULTS: 
Stable expression of FasL constructs in Schwann celIlines 
To investigate the proteins associated with FasL within the nervous system, we 
first created stable Schwann cell transfectants expressing wild type or truncated FasL 
constructs. Schwann celIs isolated from mouse sciatic nerve which later transformed in 
celI culture were used for the establishment of stable transfectants. These celIs expressed 
the Schwann celI markers S lOO and glial fibrillary acidic protein (GFAP), but not the 
fibroblast marker Thy1.2 (Fig. lA). Wild type FasL-FLAG (wtFasL), FasL-FLAG 
lacking amino acids 2-33 (FasL62-33), which inc1ude the casein kinase consensus 
sequence, and FasL-FLAG lacking amino acids 2-70 (FasL62-70), which encode the 
proline rich domain (Fig. lB), were stably expressed in Schwann celIs in conjunction 
with the enhanced green fluorescent protein (EGFP), using a bicistronic approach. The 
bicistronic vector, pIRES2, contains an internaI ribosomal entry site (IRES) upstream of 
the EGFP gene, resulting in co-translational expression of FasL and EGFP on the same 
mRNA. As expected, the ratio of FasL to EGFP mRNA was similar for all three FasL 
constructs (Fig. 1 C). However, we noticed dramatic differences in the ratios of FasL to 
EGFP protein expression between the different FasL constructs (Fig. ID). While wtFasL 
was expressed at very low levels compared to EGFP, the ratio of FasL62-33 to EGFP 
was roughly 10 fold higher. The expression ratio of FasL62-70 to EGFP was also 
increased 6 fold relative to wt FasL. Our results suggest that truncations in the coding 
region of FasL do not alter the transcriptional efficiency of FasL with respect to EGFP, 
but may increase the translational efficiency or stability of the protein in Schwann cells. 
Previous reports have documented increased translation and decreased cytotoxicity of 
FasL constructs after deletion of the intracellular region of FasL [95,96]. It is therefore 
possible that the dramatically greater expression of the FasL deletion mutants compared 
to the wtFasL protein may be attributed to increased translational efficiency and/or 
decreased cytotoxicity. 
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Fig. 1: FasL deletion mutants are expressed more efficiently than wtFasL 
A: CharacterÏzations of Schwann cells used in our experiments were performed, as 
described in the materials and methods, via flow cytometry using antibodies against glial 
fibrillary acidic protein (GFAP), S100, and the fibroblast marker Thy1.2 B: The 80 
amino acid FasL intraceIlular domain is shown in biochemical single letter code. Sites of 
truncation for FasL constructs (b.33, b. 70), the proline rich region, and casein kinase 
phosphorylation consensus are indicated. C: Stably transfected Schwann cell clones 
expressing bicistronic wildtype (Wt) or truncated FasL-lRES-EGFP constructs were 
analysed for expression ofFasL constructs. FasL and EGFP mRNA, as weIl as the 18S 
rRNA, were amplified by RT-PCR to examine the relative expression ofFasL and EGFP 
message. Densitometric values were normalized to 18S rRNA to control for loading 
differences. Graphs show the ratios ofFasL to EGFP mRNA for each construct. D: 
Lysates from Schwann cells expressing Wt and truncated FasL were subjected to 
immunoblotting for FasL and EGFP. Graphs show the densitometric ratios ofFasL to 
EGFP protein expression for each construct. Blots and ratios are representative of 
multiple Schwann ceIl clones expressing each construct. 
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Screen for FasL interacting proteins in Schwann cells 
We used Schwann cells expressing FasLâ2-33 for our screen due to the poor 
expression ofwtFasL (Fig. ID), and because previous screens in T cells failed to detect 
proteins able to interact with GST -FasL2-29 [45]. Lysates from Schwann cells 
expressing FasLâ2-33 were immunoprecipitated under gentle conditions to identify FasL 
interacting proteins. When IPs were run on gel and stained with colloidal Coomassie, six 
bands at approximately 37,52,60, 71, 74 and 110 kDa were uniquely present or greatly 
increased in anti-FLAG IPs versus control IgG IPs (Fig. 2). Using LC-MSMS, we 
identified these proteins as FasL, Protein Kinase C and Casein Kinase Substrate in 
Neurons 2 (PACSIN2; Syndapin2), PACSIN3/Syndapin3, Sorting Nexin Associated 
Golgi protein 1 (SNAG1; Sorting Nexin 18; SNX18 - present in 2 bands at 71 and 74 
kDa), and adaptin 13, respectively (Table 1). Of the proteins identified, the SH3 domain-
containing adaptor proteins P ACSIN2 and 3 have been previously reported to interact 
with the proline rich region ofFasL in T cells, validating our screen and suggesting that 
these two interactions are conserved in multiple cell types [45]. 
Fig. 2: FasL specifically co-
immunoprecipitates six bands 
FasL was immunoprecipitated from 
Schwann cells expressing FasLâ2-33, 
run on 4-20% gradient SDS-PAGE, and 
stained with colloidal Coomassie Blue. 
Six bands at 37, 52, 60, 71, 74 and 110 
kDa uniquely present or greatly 
increased in anti-FLAG IPs versus 
control IgG IPs are indicated with 
arrows. These bands and the 
corresponding gel regions from the 
control IPs were excised for 
identification using LC-MSMS. 
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Table 1: LC-MSMS Proteins "Hits" Co-precipitated with Human FasLA33 in Murine 
Schwann CeUs 
Band 
Mol. Predicted # of Sequence UniProt Accession 
Protein Name(s) Wt. Mol. Wt. Peptides Coverage # 
Fas Ligand 35kDa 37kDa 18 20% gil2168140 
Protein Kinase C and Casein 
Kinase Substrate in Neurons 
3(PACSIN3);Syndapin 3 52kDa 48kDa 3 4% gi111127644 
Protein Kinase C and Casein 
Kinase Substrate in Neurons 2 
(PACSIN2); Syndapin 2 60kDa 56kDa 13 30% gi119483913 
Sorting Nexin Associated Golgi 
Protein 1; Sorting Nexin 18 71kDa 68kDa 9 18% gtlfJ?~_:l~~}l 
Sorting Nexin Associated Golgi 
Protein 1; Sorting N exin 18 74kDa 68kDa 3 7% gi126342577 
Beta Adaptin Subunit 110kDA 98kDa 4 5% gmJ~Q:H?:?_7. 
Validation ofFasL interaction with adaptin 13 
Encouraged by the presence ofpreviously reported FasL interacting proteins in 
our screen (Table 1), we proceeded to validate novel interactions by immunoblotting 
FasL IPs prepared from Schwann cells stably expressing FasLb,2-33 and FasLb,2-70. 
Antibodies to adaptin 13 detected a band at approximately 100kDa co-precipitating with 
both FasL deletion mutants (Fig_ 3A), indicating that the proline rich region ofFasL was 
not necessary for this interaction. Unsurprisingly, adaptin 13 contains no proline binding 
motifs, although it contains an appendage do main that interacts directly with c1athrin in 
vitro [149]. 13 adaptins make up one ofthe two large subunits present in each of the 
heterotetrameric adaptor protein (AP) complexes that bind 'cargo' proteins and facilitate 
the formation of clathrin coated vesicles [150]. Each ofthese heterotetrameric AP 
complexes possesses a unique subunit composition: 131 is present with 'Y adaptin in the 
AP-l complex, and 132 with a adaptin in the AP-2 complex_ We sought to distinguish 
which AP complex bound to FasL using antibodies to these unique subunits. Although 
appropriate bands were observed in celllysates with antibodies to 'Y and a adaptins, no 
corresponding bands were detected in control or FasL IPs (Fig. 3B). 
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Validation ofFasL interaction with SNX18 
Fig. 3: Adaptin B co-precipitates 
withFasL 
A: Lysates from Schwann cells 
expressing FasLb.2-33 or 
FasLb.2-70 were 
immunoprecipitated using control 
or FLAG antibodies and 
subjected to immunoblotting for 
FasL and adaptin p. Co-
precipitation of adaptin p with 
both FasLb.2-33 and FasLb.2-70 
indicates that the FasL proline 
rich region is not necessary for 
this interaction. B: Lysates from 
Schwann cells expressing 
FasLb.2-33 or FasLb.2-70 were 
immunoprecipitated as above and 
blotted for adaptin a or adaptin y. 
Bands present in the lysate lanes 
indicate proper recognition of the 
respective proteins in the 
immunoblot, although co-
precipitation with FasL was not 
detected. 
Sorting Nexins are a family of30 proteins involved in endocytosis and protein 
trafficking. This protein family is characterized by the presence of a Phox (PX) domain, 
which binds various phosphatidylinositol phosphates, targeting the proteins to cellular 
membranes. SNX18 contains an amino terminal SR3 domain, a PX domain, and a 
carboxyl terminal coiled co il (CC) domain. As no antisera to SNX18 were available to 
validate the interaction with FasL, we immunized rabbits with SNX18-derived peptides 
conjugated to Keyhole Limpet Remocyanin. The resulting antisera reproducibly 
recognized a protein band of approximately 50 kDa and multiple bands of 68-74 kDa in 
Schwann cells (Fig. 4) and mouse tissues (data not shown). In agreement with our mass 
spectrometrie data (Table 1), an antisera-reactive band of approximately 74kDa co-
precipitated with FasLb.2-33, but not with FasLb.2-70. An additional band, not detected 
in our screen, at approximately 50 kDa also co-precipitated with FasL. The inability of 
the FasLb.2-70 construct to co-precipitate significant amounts of either band suggests 
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that the binding of SNX18 to FasL requires an intact proline rich region, and may 
therefore be mediated by the SH3 domain ofSNX18. 
kDa: 
Lysate: . 
~2-33 D.2 --70 
37 
Immunoprecipitation: 
.:\2-33 1.\2-70 Immuno 
FLAG IgG FLAG blot : 
.. 
SNX18 
.... 
FasL 
Figure 4 
Fig. 4: SNX18 co-precipitates with FasL 
Lysates from Schwann cells expressing FasLf12-33 or FasLf12-70 were 
immunoprecipitated using control or FLAG antibodies and subjected to immunoblotting 
with antibodies to FasL and antiserum to SNX18. Bands at 74 and 50 kDa (arrows) co-
precipitated with FasLf12-33, but not with FasLf12-70, indicating that the proline rich 
region ofFasL is likely necessary for this interaction. 
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DISCUSSION: 
In this report, we present the first investigation of FasL interacting proteins in 
cells of the nervous system. Our screen identified four FasL interacting proteins, two 
previously reported in T cells, PACSIN 2 and 3, and two novel FasL interactors, SNX18 
and adaptin J3. 
SNX18 represents a novel FasL interacting protein in Schwann cells. Our 
antisera reacted with multiple bands present at 68-74 kDa, of which only the band at 
74kDa co-precipitated with FasL (Fig. 4). Interestingly, SNX18 is phosphorylated on 
serine and tyrosine residues downstream of multiple receptor tyrosine kinases (JBC, 
unpublished data), and these bands may correspond to differentially phosphorylated 
SNXI8. In support ofthis hypothesis, phosphorylation of SNX9, the most closely 
related member of the sorting nexin family, has previously been shown to alter the 
cellular target of its SH3 domain in vitro [151]. 
Although there are to date no published data on the cellular functions of SNXI8, 
insights into the potential consequences of its association with FasL can be gleaned by 
comparison with its closest homologue, SNX9. SNX9 contains a domain architecture 
identical to SNX18 and is 35% homologous at the amino acid level. SNX9 was 
originally identified as an interactor with two members of the A Disintegrin And 
Metalloprotease (ADAM) family, ADAMs 9 and 15 [152]. Interestingly, members of 
this family have recently been identified as the prote as es responsible for the shedding of 
the FasL extracellular domain from the cell surface to generate soluble FasL (sFasL) 
[103]. SNX18 associated with FasL may therefore recruit ADAMs to FasL, promoting 
FasL shedding from the membrane. Furthermore, SNX9, as well as SNXI8, associate 
with the Ras activating protein SOS [153], potentially linking FasL to the ERK signaling 
pathway and providing a mechanism for FasL reverse signaling via ERK. As in T cells, 
we also observe ERK activation in Schwann cells upon stimulation of FasL with 
agonistic antibodies or Fas fusion proteins (PBT, unpublished data), suggesting that this 
pathway is conserved across cell types. Finally, SNX9 also associates with the J32 
adaptin subunit of the AP-2 complex [154], stimulates the budding step of endocytosis 
via activation of the GTPase activity of dynamin [155], and participates in the activation 
dependent degradation of the epidermal growth factor receptor [156]. Therefore, it is 
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interesting to hypothesize that SNX18 may participate in the downregulation of cell 
surface FasL either by facilitating its internalization, or by promoting extracellular 
domain shedding of the protein. 
Our screen also identified J3 adaptin as a novel FasL interacting protein. We 
detected adaptin J3 associated with both FasL~2-33 and FasL~2-70 in Schwann cells 
(Fig. 3). FasL contains no YXX<t> or di leucine sorting signaIs known to bind to the 
adaptor protein complexes. Our antibodies recognize both J31 and J32 adaptin which are 
82% homologous at the amino acid level, and we were un able to co-precipitate the AP-l 
or AP-2 specific subunits, 'Y or a adaptin, with FasL. Our data suggest that the interaction 
between FasL and adaptin B is mediated via the 10 amino acids in the cytoplasmic tail of 
FasL that are still present in FasL~2-70. These remaining cytoplasmic residues of FasL 
contain the sequence KKRn-74, which is ubiquitinated [131]. Ubiquitination has been 
associated with the internalization of many cell surface proteins [157], and may therefore 
indirectly recruit B2-adaptin for the internalization of FasL. In support of this, FasL 
constructs with these lysine residues mutated are expressed more readily at the cell 
surface compared to wild type FasL [113]. The association of FasL with adaptin J3 may 
be an important regulator of the surface expression of the protein and hence control both 
FasL forward (via Fas) and reverse signaling. 
Our screen further identified the PACSIN proteins 2 and 3 as FasL interacting 
proteins in Schwann ceIls, confirming previous findings in T cells and suggesting that 
these interactions are conserved in multiple cell types. The three known PACSIN 
proteins aIl contain an SH3 domain and a coiled coil domain, and are highly implicated 
in endocytosis. By binding the Wiskott Aldrich Syndrome Protein (WASP), a potent 
activator of actin nuc1eation, and the OTPase dynamin, they are thought to link 
endocytosis to the actin cytoskeleton [134]. Based on colocalization data, the se proteins 
may aIso participate in the lysosomaIlocalization of FasL [133]. Similar to the Sorting 
Nexins, PACSIN proteins also bind to members of the ADAM metaIloprotease family 
and regulate ectodomain shedding of the pro-heparin binding EOF-like growth factor 
[137]. 
Several previous studies have used OST pulldowns to examine FasL protein 
interactions in T cells [45,46]. Most of the FasL interacting proteins identified appeared 
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to attenuate the cell surface expression of FasL and/or alter its subcellular localization 
[131,133,138,143,158], rather than participate in FasL reverse signaling. This is 
consistent with reports documenting increased expression of FasL at the cell surface 
upon deletion ofits proline rich domain [113,131]. Clearly, the presence of multiple 
FasL interacting proteins in T cells, as well as in Schwann cells, with roles in regulating 
its localization highlight the need for tight regulation of both the effector and reverse 
signaling activities of FasL. This tight regulation of its surface expression makes 
intuitive sense, as cell surface expression of FasL would need to be tightly regulated to 
ensure appropriate regulation of apoptotic signaIs. FasL reverse signaling, by contrast, is 
often cited as weak or modest. Our screen may have missed potential reverse signaling 
effectors due to the deletion of FasL amino acids 2-33; however, a previous report failed 
to identify biding partners for GST-FasL2-29 [45]. 
In summary, our screen for FasL interacting proteins within Schwann cells has 
identified two novel proteins, and confirmed two known FasL interactors, ail with 
potential functions in regulating trafficking and subcellular localization. The recurring 
theme of these interacting proteins within cells of both the nervous and immune systems 
highlights the need for tight regulation of cell surface expression of FasL, and 
identification of these novel FasL interactors provides insight into potential molecular 
mechanisms underlying this stringent regulation. 
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TRANSITION TO CHAPTER 3: 
In addition to FasL interacting proteins identified using mass spectrometry in 
Schwann cells (see Chapter 2), candidate SR3 and other proline binding domain 
containing proteins were also tested in parallel for co-immunoprecipitation with FasL, 
when antibodies were available. Ofthe many proteins tested, only one convincingly 
interacted with FasL. Chapter 3 contains experiments performed to establish the adaptor 
protein Grb2 as a FasL interacting protein in Schwann cells and determine the 
significance ofthis interaction. 
The significance ofthe Grb2-FasL interaction was researched more extensively in 
comparison to the other interacting proteins identified by LC-MSMS in Chapter 2 simply 
because it was the first interacting protein identified by the author and used as a positive 
control during the troubleshooting phase of the LC-MSMS experiments. Although we 
did not subject gel bands at a molecular weight that would contain Grb2 to LC-MSMS in 
the experiments in Chapter 2 (due to potential interference from antibody light chains in 
detection by mass spectrometry), we did notice an increase in the appropriate band at 25 
kilo Daltons (see Figure 2 in Chapter 2). 
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Chapter 3 
The Adaptor Protein Grb2 Interacts with 
Fas Ligand and Regulates its Cell Surface 
Expression in Schwann cells 
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ABSTRACT: 
Fas Ligand (FasL) binds Fas (CD95) to induce apoptosis or activate other 
signaling pathways. The intracellular domain of FasL contains an extended proline rich 
region which modulates the surface expression of the molecule via interacting with 
protein complexes. Rere, we identify the SR3 domain containing adaptor protein, Grb2, 
as a regulator of FasL surface expression in Schwann cells. Mutational analyses suggest 
that Grb2 binds to the proline rich region of FasL. Knockdown of Grb2 results in altered 
FasL distribution, with FasL decreased on the cell surface and increased intracellularly. 
Our data show that Grb2 controls the subcellular localization of FasL, either by retaining 
it at, or sorting it to the cell surface. 
Key Words: Fas Ligand, Src homology 3 domain, Schwann cell, Grb2, sorting nexin 18, 
adaptin ~ 
Thornhill, pg. 52 
INTRODUCTION: 
Fas Ligand (FasL, CD95L, CD178) is a homotrimeric protein with membrane-
bound and soluble isoforms, and belongs to the tumor necrosis factor (TNF) superfamily. 
FasL is expressed by activated immune cells, and in "immune privileged" tissues such as 
the eye and the nervous system [72] [70,71,144]. The extracellular domain of FasL binds 
to the Fas receptor (CD95) to induce apoptosis [10,145]. In addition to the effector 
function of FasL as an inducer of apoptosis, FasL and other membrane-bound TNF 
superfamily ligands can also transduce "reverse signaIs" and thus participate in 
bidirectional signaling [118,126]. 
As FasL is a transmembrane protein able to induce apoptosis, its cell surface 
expression must be tightly regulated. Cell surface FasL is c1eaved via the action of 
metalloproteinases [98,103], liberating a soluble FasL (sFasL) extracellular domain, 
which has limited potency as an apoptosis inducer [99]. Transmembrane FasL can also 
be released extracellularly via secretion of microvesic1es bearing FasL [112,117]. 
Multiple reports have documented significant intracellular retenti on of FasL [58,111-
113,159]. In cells with secretory lysosomes, su ch as cytotoxic T lymphocytes and mast 
cells, FasL is predominantly intracellular and colocalizes with lysosomal markers, while 
cells lacking these specialized organelles express cell surface FasL with variable levels of 
intracellular retenti on [58,95,113]. The FasL intracellular domain (ICD) is likely 
sufficient for its intracellular retention, as fusion of the FasL ICD to the cell surface 
protein CD69 results in intracellular retention of the fusion protein [58]. The FasL 
intracellular domain contains several putative consensus sequences for phosphorylation, 
and a 26 amino acid proline rich region capable of interacting with proteins containing 
Src homology 3 (SR3) and WW domains [45,46]. The proline rich region has been 
implicated in regulating surface expression of FasL through via interacting with several 
of these SR3 domain containing proteins [113,138,143]. 
We have recently found that FasL interacts with multiple trafficking-associated 
proteins in Schwann cells [160]. Schwann cells are the glial cells of the peripheral 
nervous system, and they upregulate FasL after peripheral nerve injury [69], suggesting 
that Fas / FasL signaling may play a role in the injured nervous system. Schwann cells 
are essential for peripheral nerve regeneration, and contribute to the extensive tissue 
Thornhill, pg. 53 
remodeling that occurs during healing. In this report, we follow up on our initial findings 
by investigating mechanisms that could regulate cell surface expression of FasL on 
Schwann cells. We identify the SH3 domain containing adaptor protein, Grb2, as a 
regulator of FasL surface localization in the nervous system. 
MATE RIALS AND METHODS: 
Cells 
Mouse Schwann cells were isolated from sciatic nerves of neonatal (Pl to P3) 
C3H/HeJ mice, as described [160]. To verify the purity of the cultures, cells were 
examined by flow cytometry for expression of the Schwann cell markers glial fibrillary 
acidic protein (GFAP) and SlOO, and the fibroblast marker Thy-1.2, as described 
previously [160]. 
Construction of FasL deletion mutants 
FasL deletion mutants, HuFasL~2-33-FLAG and HuFasL~2-70-FLAG, were created 
using wildtype FasL cDNA as a template to produce PCR products missing base pairs 
corresponding to N-terminal amino acids 2-33 and 2-70, respectively, but still containing 
the initiator methionine (AUG) base pairs. Vector construction methodology has been 
previously described [160]. AIl vectors were fully sequenced before transfecting into 
cells to ensure the absence of mutations/frameshifts created during PCR amplification. 
Creation of stably transfected celllines 
Mouse Schwann cells were transfected with huFasL-FLAG, huFasL~2-33-FLAG, 
huFasL~2-70-FLAG, or empty pIRES2-EGFP vector. EGFP-positive cells were single 
cell sorted into 96 weIl plates using a FACSAria™ fluorescence activated cell sorter (BD 
Biosciences, Mississauga, ON), expanded in standard media supplemented with 400 
!-tg/ml G418 (Wisent Bioproducts, St. Bruno, QC), and screened for expression of FasL 
constructs and EGFP by immunoblotting. . 
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RNA interference (RNAi) 
Cells were trypsinized and transfected while still in suspension with 5nM mouse Grb2 
ON-TARGETplus SMARTpool or ON-TARGETplus siCONTROL Non-Targeting 
siRNA (Dharmacon, Lafayette, CO) using Lipofectamine RNAimax (lnvitrogen, 
Burlington, ON) according to the manufacturers' recommendations. cens were then re-
transfected 24 hours after attachment to maximize knockdown. In an experiments, 
knockdown was confrrmed 48 hours after initial transfection by immunoblotting. 
Immunoprecipitation (IP) and Immunoblotting 
For IP, cens were washed once in phosphate-buffered saline (PBS) and lysed in buffer 
containing 0.5% Nonidet P-40 (Bioshop Canada, Burlington, ON), 25mM HEPES pH 
7.4, 115 mM potassium acetate, 5mM magne sium chloride, 1 mM sodium orthovanadate 
(an from Sigma-Aldrich, Oakville, ON), and Complete Mini™ protease inhibitor 
cocktail (Roche Diagnostics, Laval, QC). Lysates remained on ice for 15 minutes before 
centrifugation at 15,000 rpm for 10 minutes at 4°C. Supematants were then precleared 
against unconjugated Sepharose 4B (Sigma-Aldrich, Oakville, ON) for 1.5 hours at 4°C. 
Sepharose beads were then pelleted, and prec1eared supematants were incubated for at 
least 2 hours at 4°C with specific or isotype control antibodies plus Protein G-Sepharose 
(GE Healthcare, Piscataway, NJ). The beads were then pelleted, washed thrice in cold 
lysis buffer, boiled in Laemmli buffer containing ~-mercaptoethanol, and 
electrophoresed on SDS polyacrylamide gels. SDS gels were then transferred to 
polyvinylidene difluoride membranes (PVDF, BioRad Canada, Mississauga, ON). 
PVDF membranes were blocked ovemight at 4°C in 5% non-fat dry milk powder (w/v) 
in Tris-buffered saline/O. 1 % Tween 20 (Fisher Scientific, Ottawa, ON; TBST) and 
blotted with the indicated primary and horseradish peroxidase (HRP) conjugated 
secondary antibodies diluted in blocking buffer and TBST respectively. Bands were 
visualized using ECL PLUSTM reagents (GE Healthcare, Piscataway, NJ) and film from 
Molecular Technologies Inc. (Phillipsburg, NJ). 
Immunofluorescence 
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Schwann cells expressing the indicated FasL constructs were grown overnight on glass 
coverslips. Cells were then fixed for 30 minutes at room temperature with 4% 
paraformaldehyde, and washed thrice with PBS/O.O 1 % Triton X -100 (Sigma-Aldrich, 
Oakville, ON). Cells were blocked and permeabilized with PBS/2% bovine serum 
albumin (Sigma-Aldrich, Oakville, ON)/O.l % Triton X-lOO for 1 hour, then stained with 
20 [lg/ml protein G purified anti-Fas Ligand antibodies (NOK-l hybridoma, International 
Patent Organism Depository) or control antibodies, followed by Cy3 conjugated 
secondary antibodies (Jackson Immunoresearch, West Grove, PA). All slides were 
counterstained with 2.5 [lg/mI4',6-diamidino-2-phenylindole (Sigma-Aldrich, Oakville, 
ON; DAPI). Stained samples were mounted on slides using Aqua Polymount 
(Polysciences Inc., Warrington, PA) and analyzed using a Leica DMIRE2 fluorescent 
microscope (Richmond Hill, ON). 
Flow Cytometry 
Cells expressing the indicated FasL constructs were detached from cell culture plates by 
vigorous pipetting, pelleted, and resuspended in PBS + 2% fetal calf serum (FCS). Cells 
were then stained on ice for 25 minutes with affinity purified NOK-l anti-FasL 
antibodies (clone obtained from International Patent Organism Depository) or control 
antibodies. After two wash cycles in PBS + 2% FCS, all samples were then stained with 
phycoerythrin conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, 
PA). Cells were washed twice more in PBS + 2% FCS and analyzed using a 
FACSArrayTM bioanalyzer (BD Biosciences, Mississauga, ON). 
Antibodies 
For IP, flow cytometry, and immunofluorescence, monoclonal anti-FLAG M2, mouse 
IgG 1 control, Rabbit IgG control (all Sigma-Aldrich, Oakville, ON), anti-Grb2 (Santa 
Cruz Biotechnology, Santa Cruz, CA), or affinity purified NOK-l anti-FasL antibodies 
were used. Anti-FasL G247.4 (BD Biosciences, Mississauga, ON), anti-adaptin P (BD 
Biosciences, Mississauga, ON) or anti-Grb2 (Santa Cruz Biotechnology, Santa Cruz, 
CA) antibodies were used for immunoblots. For the detection of sorting nexin 18, anti-
SNX18 antibodies were generated by immunizing rabbits, as previously described [160]. 
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RESULTS: 
Cell Lines 
We have previously characterized the Schwann celIlines stably expressing wild type 
and truncated FasL constructs that we use here. These Schwann celIlines are GFAP+, 
S100+, Thy-l-, and constitutively express wildtype FasL-FLAG (wtFasL), FasL-FLAG 
lacking the casein kinase consensus sequence but including the proline-rich domain 
(FasLâ2-33), or FasL-FLAG lacking the proline rich domain (FasLâ2-70; Fig. 1). We 
and others have previously found that intracellularly truncated forms ofFasL are 
expressed much more efficiently than wtFasL due to increased translational efficiency 
and/or decreased cytotoxicity oftruncated FasL constructs [95,96,160]. Due to the 
extremely low expression ofwtFasL (Fig. 1), and because we have previously shown that 
FasLf12-33 and wtFasL both interact with the same novel binding partners in Schwann 
cells [160], we therefore chose to use FasLf12-33 to investigate potential mechanisms of 
FasL trafficking in Schwann cells. 
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Fig. 1: FasL deletion mutants are expressed more efficiently than wtFasL 
A: The 80 amino acid FasL intraceUular domain is shown in biochemical single letter 
code. Sites oftruncation for FasL constructs (f133, f170), the proline rich region, and 
casein kinase phosphorylation consensus are indicated. B: Lysates of stably transfected 
Schwann ceU clones expressing bicistronic wild type (Wt) or truncated FasL-lRES-
EGFP constructs were run on SDS-PAGE and immunoblotted to demonstrate relative 
expression ofFasL and EGFP. Graph at right shows the densitometric ratios ofFasL to 
EGFP protein expression for each construct. Blots and ratios are representative of 
multiple Schwann ceU clones expressing each construct. 
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Interaction of Grb2 with FasL 
In order to identify FasL interacting proteins that may act as regulators ofFasL surface 
expression, we examined co-immunoprecipitation of candidate SR3 domain-containing 
proteins with FasLâ2-33 in Schwann cells. Grb2, an adaptor protein containing one SR2 
and two SR3 domains, has previously been implicated in receptor downregulation 
[127,161] and is a known FasL interacting protein in T cells [45]. When FasLâ2-33 
immunoprecipitates were immunoblotted for Grb2, we detected efficient co-precipitation 
with FasL (Fig. 2A). Grb2 co-precipitated with FasL immunoprecipitated with 
antibodies to FasL (clone NOK-l), as well as to the FLAG epitope. The NOK-l 
antibody was less efficient at precipitating FasLâ2-33 than the anti-FLAG antibody, and 
also co-precipitated less Grb2, consistent with a specific interaction. Antibodies to Grb2 
also co-precipitated FasL from FasLâ2-33 Schwann celllysates (Fig. 2B). We detected 
FasL in Grb2 immunoprecipitates from cells expressing FasLâ2-33, but not FasLâ2-70, 
suggesting that the interaction with Grb2 requires an intact proline rich domain. 
A Immunoprecipitation: 
I,ysate 
IgG FLAG NOK-l 
37 
B 
Immunoprecipitation: 
Lysate: ~2-33 ~2-70 
~2 -33 ~2 -70 IgG Gr:Q2 IgG Grb2 
25 
Immuno 
blot: 
Grb2 
FasL 
Immuno 
blot: 
FasL 
Grb2 
Fig. 2: Grb2 co-
precipitates with amino 
acids 34-70 ofFasL 
A: Lysates from 
Schwann cells expressing 
FasLâ2-33 were 
immunoprecipitated 
using control, NOK-l 
anti-FasL, or FLAG 
antibodies and subjected 
to immunoblotting for 
FasL, Grb2 B: Lysates 
from Schwann cells 
expressing FasLâ2-33 or 
FasLâ2-70 were 
immunoprecipitated with 
control or anti-Grb2 
antibodies and blotted for 
and immunoblotted as 
above. Co-precipitation 
of FasLâ2-33 , but not FasLâ2-70, suggests that Grb2 interacts with the proline rich 
region ofFasL encoded in amino acids 34-70. 
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Grb2 positively regulates cell surface FasL 
We next investigated the effect of Grb2 on FasL surface expression using RNAi to 
Grb2. Grb2 has previously been shown to downregulate the expression of the epidermal 
growth factor receptor (EGFR) [127,161]. Unexpectedly, flow cytometric staining of 
Schwann cells revealed significant (p<O.01) attenuation of cell surface expression of 
FasL62-33, but not FasL62-70, 48 hours after Grb2 knockdown (Fig. 3A, B). 
Immunofluorescent staining of FasL on the Schwann celllines also demonstrated 
reduced surface expression of FasL62-33 after Grb2 but not control non-targeting RNAi 
treatment (Fig. 3C, D). In control cells, FasL staining was observed on the surface of 
lamellipodial-like extensions, as weIl as extracellularly on FasL-bearing microvesicles. 
After Grb2 knockdown, this staining was shifted to the submembrane space, with 
punctuate FasL staining within each cell. Quantification by a blinded observer revealed a 
significant increase (p<O.0001) of the number of FasL staining puncta per cell following 
Grb2 knockdown in FasL62-33 but not in FasL62-70 Schwann cells, despite efficient 
knockdown in both celllines (Fig. 3 C,D). Grb2 knockdown therefore decreases FasL 
surface expression and increases its expression in an intracellular compartment. 
Collectively, these data imply that Grb2 promotes the cell surface expression of FasL and 
affects its subcellular localization in Schwann cells. 
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Fig. 3: Grb2 regulates the surface expression of FasL 
A: Schwann cells expressing FasL~2-33 or FasL~2-70 were treated with control non-
targeting or Grb2 siRNA's, stained for surface FasL expression and analyzed using flow 
cytometry. Thick lines represent samples given control siRNA treatment, while thin 
lines represent groups treated with Grb2 RNAi. B: In a separate experiment, cells were 
treated and stained as above in triplicate wells and similarly analyzed using flow 
cytometry. Geometric Mean Fluorescence intensities (MFI) are plotted. Significant 
decreases in (MF!) corresponding to surface expression were observed in Schwann cells 
expressing FasL~2-33 (p=0.0092; two tailed t test), but not FasL~2-70 (p=0.4001). C: 
Lysates of Schwann cells expressing FasL~2-33 and FasL~2-70 were run on SDS-
PAGE and immunoblotted for Grb2 and actin following control or Grb2 siRNA 
treatment to confirm knockdown. Typical results are shown. D: Schwann cells 
expressing the indicated FasL constructs were treated with control or Grb2 siRNA and 
analyzed using indirect immunofluorescence following staining for FasL. Red staining 
represents FasL, while blue represents DAPI nuc1ear staining. E: Quantification of 
intracellular puncta like staining of FasL before and after Grb2 RNAi treatment 
performed by a blinded observer. Schwann cells expressing FasL~2-33 displayed an 
increased number of puncta per cell (p<O.OOOI; two tailed t test) but not cells expressing 
FasL~2-70 (p=0.0778). Data are representative of multiple trials. 
Grb2 interacts with novel FasL interacting proteins 
As an adaptor protein with multiple protein binding domains, but no inherent catalytic 
activity, Grb2likely mediates its effect on FasL surface expression via linking it to other 
protein complexes. We have recently identified two novel FasL interacting proteins in 
Schwann cells [160], Sorting Nexin 18 (SNXI8) and adaptin ~, both with recognized 
roles in protein trafficking [150,162]. Both proteins contain the minimal PXXP motifs 
necessary for SR3 domain binding (NCBI database accessions Q10567, Q96RFO). We 
therefore tested the ability of SNX18 and adaptin ~ to interact with Grb2 in our Schwann 
celllines, using co-IP. Surprisingly, both proteins were specifically co-precipitated by 
antibodies to Grb2, but not by control antibodies (Fig. 4). To our knowledge, both of 
these represent novel protein interactions, not previously reported in the literature. As 
these two proteins both co-precipitated with FasL as well as with Grb2 in Schwann ceIls, 
we next sought to determine whether their interactions with FasL were dependent on 
Grb2. Knockdown of Grb2 preceding immunoprecipitation of FasL did not appreciably 
attenuate the level of co-precipitated SNXI8, despite efficient knockdown of Grb2 (Fig. 
5A, B). In contrast to SNXI8, co-precipitation of adaptin ~ with FasL was dramatically 
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reduced by Grb2 knockdown (Fig. 5A), suggesting that the interaction between FasL and 
adaptin ~ is dependent on Grb2. 
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Fig. 4: Grb2 interacts with the FasL interacting proteins Sorting Nexin 18 and adaptin ~ 
Lysates from Schwann cells expressing FasLâ2-33 were immunoprecipitated using 
control or anti-Grb2 antibodies, run on SDS-PAGE and subjected to multiple rounds of 
immunoblotting for Grb2, Sorting Nexin 18, and adaptin~. Co-precipitation ofFasL 
interacting proteins was observed in Grb2 but not control IPs. (HC-IgG heavy chain) 
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Fig. 5: Grb2 knockdown attenuates FasL-adaptin B co-precipitation 
A: Schwann cells expressing FasLâ2-33 were pretreated with control or Grb2 siRNAs, 
then lysed, and immunoprecipitated with control or FLAG antibodies. Samples were run 
on SDS-PAGE, followed by, repeated immunoblottings for FasL, Sorting Nexin 18 and 
adaptin B. B: Control and Grb2 RNAi treated Schwann celllysates from the above 
experiment were run in parallel on SDS-PAGE and blotted for Grb2 to confirm efficient 
knockdown. 
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DISCUSSION: 
In this report, we document a role for the adaptor protein Grb2 in the trafficking 
and surface expression of FasL. We also provide the first evidence that Grb2 binds to 
two recently described FasL interacting proteins, SNX18 and adaptin~. FinalIy, we 
show that Grb2 promotes the interaction between FasL and adaptin ~, suggesting a 
potential mechanism for the regulation of FasL trafficking by Grb2. 
Our data indicate that amino acids 34-70 of FasL, containing its proline rich 
region, are necessary for the interaction between Grb2 and FasL. In Schwann cells 
expressing FasL that contains the proline rich region, we observe a redistribution of FasL 
from the cell surface to an intracellular compartment following attenuation of Grb2 
expression. These data suggest that Grb2 interacts with FasL via its SH3 domain, and 
promotes sorting or retention of FasL at the cell surface. FasL~2-70, which does not 
contain the proline rich region and does not interact with Grb2, does not undergo 
redistribution when Grb2 is knocked down. However, it must be noted that the 
expression of FasL~2-70 is significantly lower than FasL~2-33 in all Schwann celIlines 
examined, and the low expression levels of FasL~2-70 may compromise our ability to 
detect it at the cell surface. 
Grb2 has previously been documented to bind FasL in T cells [45,122], where it 
has been hypothesized to mediate FasL reverse signaling via recruitment of SOS, to 
activate Ras and the extracellular-signal regulated kinase (ERK) MAPK pathway 
[70,122]. However, Grb2 has not previously been implicated in FasL trafficking. 
Interestingly, Grb2 has been shown to mediate the internalization of the epidermal 
growth factor receptor (EGFR) [127,161,163], whereas we show that Grb2 promotes 
accumulation of FasL at the cell surface. 
We then investigated the mechanism by which Grb2 altered the subcellular 
localization of FasL. We have recently described two novel protein interactions with 
FasL in Schwann celIs, SNX18 and adaptin ~. We have previously reported that SNX18 
binds to amino acids 34-70 of FasL [160], and we show here that its interaction with 
FasL does not depend on Grb2 (Fig. 5). Adaptin~, on the other hand, appears to require 
Grb2 for its interaction with FasL (Fig. 5). Adaptin ~ contains a proline rich stalk region 
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(AAs 576-725; QI0567) forming a putative SH3-binding domain which may allow it to 
interact with Grb2. Grb2 may therefore act as an adaptor protein for the interaction of 
FasL and adaptin~. It is also possible that Grb2 may stabilize a trimeric complex of 
FasL, adaptin ~, and Grb2, involving several SH3 domain interactions. 
~ adaptins are an essential component of the adaptor protein (AP) complexes that 
bind 'cargo' proteins and c1athrin, and facilitate the formation of c1athrin coated vesic1es 
for protein sorting [164]. For ex ample , the AP-l complex facilitates budding from the 
trans-Golgi network (TGN) and endosomes, while the AP-2 complex mediates budding 
from the cell surface. The Grb2-dependent recruitment of adaptin ~ to FasL may 
therefore underlie its ability to promote accumulation of FasL at the cell surface. 
Severa! previous studies have used GST pulldown approaches to examine FasL 
protein interactions in T cells [45,46]. Most of the FasL interacting proteins identified 
appeared to attenuate the cell surface expression of FasL and/or alter its subcellular 
localization [133,138,143]. Here we document a protein-protein interaction with FasL 
that appears to increase its cell surface expression in Schwann cells. Clearly, the 
presence of multiple FasL interacting proteins in T cells, as well as in Schwann cells, 
with roles in regulating its localization highlight the need for tight regulation of the 
effector activity of FasL. FasL is upregulated in Schwann cells after injury to the 
nervous system [69], suggesting that FasL apoptotic or reverse signaling activities play a 
role in regeneration in the peripheral nervous system. In fact, we have previously found 
that peripheral nerve regeneration is delayed in mice with hypofunctional Fas or FasL 
[21] (and unpublished data), suggesting that regulation of cell surface FasL on Schwann 
cells may be critical during nerve regrowth. 
In summary, we have identified Grb2 as a key regulator of FasL surface 
expression in Schwann cells, and we have shown that Grb2 recruits or stabilizes the 
association of adaptin ~ with FasL, providing a potential mechanism for control of FasL 
trafficking by Grb2. Our findings demonstrate a new molecular mechanism for 
regulating the intracellular localization of FasL, a molecule implicated in apoptosis and 
peripheral nerve regeneration. 
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Chapter 4 
Final Conclusions 
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CONCLUSION: 
In this thesis, we used a proteomic approach to identify novel FasL interacting 
proteins in Schwann cells, the glial cells of the peripheral nervous system, to gain insight 
into mechanisms ofreverse signaling and trafficking ofFasL in the nervous system. 
Using liquid chromatography-tandem mass spectrometry (LC-MSMS) for identification 
ofFasL co-immunoprecipitating proteins (Chapter 2), we identified Sorting Nexin 18 
(SNX18), adaptin~, Protein Kinase C and Casein Kinase Substrate in Neurons 2 
(PACSIN2), and PACSIN3 as FasL interacting proteins. Using a parallel, candidate 
approach we also identified Grb2 (Chapter 3), as a FasL binding protein. The binding of 
FasL to multiple proteins implicated in trafficking suggests tight regulation ofthe reverse 
signaling and effector functions ofFasL within the nervous system. As mice with 
hypofunctional Fas or FasL exhibit delayed peripheral nerve regeneration, and Schwann 
cells are essential for proper regeneration, factors which regulate Schwann cell surface 
FasL, where it is available to bind Fas, may play important roles in nervous repair. 
Although in Chapter 2 we identified several novel FasL interacting proteins, 
which were verified by immunoblotting, significant work remains to elucidate the 
function ofthese novel interactors in Schwann cells. Figure 1 (below) summarizes 
potential functions these proteins as FasL interactors based on the literature. 
How FasL interacting groteins may regulate FasL: 
4. Internalization 
2. Coated Pit 
Formation 
Fig. 1 Potential Function ofFasL interacting proteins identified in this thesis 
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r-... Via interacting with members of the metalloproteinase family, as well as FasL, 
Sorting Nexin 18 and P ACSIN3 may regulate the extracellular do main shedding (1) of 
FasL [137,152]. Interestingly, it has been documented that siRNA targeting PACSIN3 
decreases extracellular do main shedding of the heparin-binding epidermal growth factor-
like growth factor [137]. Coiled coil domains present in these proteins, which allow 
them to oligomerize [162], could allow them to function as adaptors in this context, with 
each monomer using its single SR3 do main to recruit the proline rich FasL and 
metalloproteinase proteins to the same complex. 
The association of FasL with adaptin ~ may facilitate the entry of FasL into 
c1athrin coated pits (2). ~ adaptins make up one ofthe two large subunits present in each 
ofthe heterotetrameric adaptor protein (AP) complexes that bind 'cargo' proteins and 
facilitate the formation of c1athrin coated vesic1es [150]. SNX9, the most c10sely related 
homologue ofSNXI8, associates with the ~2 adaptin subunit of the AP-2 complex [154] 
and stimulates the budding or fission step of endocytosis (3) via activation ofthe GTPase 
activityofdynamin [155]. PACSIN proteins also bind to dynamin [134] and it is 
therefore interesting to hypothesize that these three proteins may act together to 
participate in the downregulation of cell surface FasL by facilitating its intemalization 
(4). 
Altematively, FasL may bind to ~1 adaptin, a subunit ofthe AP-l complex, and 
may act to facilitate budding from AP-1 target membranes, such as the Golgi apparatus 
and endosomes. Our attempts to identify which AP complex bound to FasL were not 
successful (Chapter 2, Fig. 3B). SNX9 can also bind to ~1 adaptin of the AP-1 complex 
[165], and the association ofFasL with SNX18 may similarly facilitate or stabilize an 
interaction between FasL and ~1 adaptin. These speculations assume a conservation of 
binding partners between Sorting Nexins 9 and 18, an assumption which has not been 
tested experimentally to date. 
In Chapter 3, in addition to identifying the adaptor protein Grb2 as a FasL 
interacting protein, we were also able to demonstrate that this protein acts as a positive 
regulator ofFasL surface expression in Schwann cells. Mutational analyses suggested 
that Grb2 binds to the proline rich region ofFasL (Chapter 3, Fig. 2) and knockdown of 
Grb2 resulted in altered FasL distribution, with FasL decreased on the cell surface and 
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increased intracellularly (Chapter 3, Fig. 3). Our data show that Grb2 controls the 
subcellular localization ofFasL, either by retaining it at, or sorting it to the cell surface. 
Interestingly, we found that Grb2 interacted with two of the above identified FasL 
interacting proteins, SNX18 and adaptin B (Chapter 3, Fig. 4). Ofthese two proteins 
which interact with both FasL and Grb2, only adaptin B required the presence of Grb2 to 
co-precipitate with FasL (Chapter 3, Fig. 5). This result suggests that Grb2 either 
directly mediates or stabilizes the interaction between FasL and adaptin B. A preliminary 
model summarizing the results from Chapter 3 is presented below as Figure 2. 
Summary: 
G rb2 is expressed: Grb2 is knocked down: 
FasL62-33 
Surface Expression 
FasLâ2-33 is retained intracellularly 
FasLb.2-33 
Fig. 2 Preliminary model summarizing the results in Chapter 3 
In the above model, we propose that the presence of Grb2 facilitates the 
interaction between adaptin Band FasL by linking together the se two proline rich 
proteins via its two SR3 domains. Although we were unable to experimentally define 
which isoform of adaptin B bound to FasL, we propose that Grb2 mediated recruitment of 
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adaptin ~l may positively regulate budding from the Golgi apparatus and endosomes of 
FasL containing vesicles destined for the cell surface (see left half of figure). In the 
absence of Grb2, this complex does not form and FasL surface expression is greatly 
attenuated (see right half of figure). 
In summary, the detailed analyses of nervous system FasL interacting proteins 
presented in this thesis highlight the multiple levels of regulation of this protein and 
provide insight into the potential mechanisms of this regulation. Factors which regulate 
the surface expression of this death factor are of obvious interest, as cell death is 
dysregulated in many disease states. A more thorough understanding of the cell 
biological mechanisms of protein trafficking may also provide insight into diseases 
where proteins are not properly trafficked, such as cystic fibrosis. 
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The following procedures have not changed: 
Sciatic nerve regeneration experiments (as a model ofperipheral nerve regeneration after trauma) 
". 
- Tagging (by ear punch) for identification of individual mice. 
- ip injection of anti-Fas Ligand antibody or control antibody, in 200lli saline. 
- Anesthesia of adult mice by avertin injection as per SOP. 
- Sciatic nerve crush surgery under avertin anesthetic. (Procedure as follows: Mice are anesthetized with avertin and prepared for 
surgery by shaving and disinfecting the right flank and leg. A l-cm long incision was made through the skin, and the gluteal and 
hamstring muscles of the upper dorsal thigh seperated to reveal the sciatic nerve. The nerve is isolated and grasped in Dumont #5 
forceps 5 mm distal to the sciatic notch. The nerve is crushed by application of pressure for 30 seconds. The crush is immediately 
repeated at the same site for an additional 30 seconds. 2 Jlg anti-Fas Ligand Ab or control Ab, in physiological saline or in fibrin or 
matrigel™ matrix, are injected into the crush site in sorne mice at this time. The muscles and skin are closed with absorbable Dexon 
sutures and the mice allowed to recover. After the frrst post-operative day, the mice stop dragging their operated limb and gradually 
resume weight-bearing. The animaIs have never been observed to gnaw on their operated paw to the point ofinjury following this 
procedure.) 
- Walking track analysis (behavioural study for weight bearing on injured limb, which consists of coating the hind paws of mice with 
India Ink, and allowing the mice to walk along an 18-inch long track lined with paper) every two days post-surgery. 
- Euthanasia as per SOP. 
- Tissue collection. 
Immunization of donor mice for induction of Experimental Allergic Enc~halomyelitis (EAE,a mouse model of Multiple Sclerosis) 
- Immunization with protein or peptide antigens (50-400 micrograms, depending on the antigen), emulsified in Complete Freund's 
Adjuvant (1:1 ratio by volume ofantigen to CFA), 100 ul subcutaneously at two sites (bilaterallynear scruffofthe neck, 50 ut per 
site). 
- Euthanasia as per SOP, 10 days after immunization. 
- Tissue collection. 
BAB induction 
- Tagging (by ear punch) for identification of individual mice. 
- iv injection ofT cells and pertussis preparation (pTX, 200ng in 200JlI saline) to induce BAB. Pertussis preparations are used here 
as an adjuvant to induce EAB, but can also potentiate insulin secretion, suppress hyperglycemia, promote leukocytosis, and sensitize 
to histamine, and it is considered biohazardous. Therefore, the foUowing precautions are routinely employed: the powdered pertussis 
(Sigma) is reconstituted in the sealed vial, then aU personal protective precautions (gloves, masks, lab coats and protective eyeware) 
are employed during reagent preparation and mouse immunization. The reagent is very unstable and after being injected into the 
mouse does not present a hazard to personnel. Pertussis has been used as an adjuvant to induce BAB since the 1960's (Levine et al., 
Hyperacute allergic encephalomyelitis: adjuvant effect ofpertussis vaccines and extracts. J Immunol. 1966,97:363-8), with, to our 
knowledge, no reported ill-effects on personnel. 
- ip injection of anti-Fas Ligand antibody injection in 200Jll saline (as above). 
- Anesthesia by avertin injection as per SOP. 
- Intrathecal injection of anti-Fas Ligand antibody in 0.21l1 saline using a stereotaxic apparatus on anesthetised mice. 
- Daily observation for BAB grading. 
- Buthanasia as per SOP at 14, 21 or 30 days following fmal injection, OR as soon as pain or distress is observed (lack of drinking, 
feeding or grooming; hunched posture; piloerection; reduced mobility). 
- Tissue collection. 
Spinal Cord Injury and Recoverv 
- Behavioral testing: walking track analysis (baseline), as described under sciatic nerve surgery, and observation ofmouse posture 
and gait during walking to determine a numerical score. 
- Anesthesia - as per SOP 
- Survival Surgery: dorsal hemisection - asper SOP, with thefollowing details pertaining to the surgical procedure: 
. One spinal cord segment in the lower thoracic region WilfOe exposed by doing a laminectomy of the vertebra. A smaIllesl0n (0.5n:un 
~'l depth) will be made in the dorsal half of the spinal cord(doiiallièmisection) using a pair of micro-scissors. 2 Jlg anti-FasL AOoi: -- . 
,
vontrol Ab, in physiolog~cal saline or in fibri~ or matrigel™ nia~lll:~applied to. the lesion ~ so~e ~ce at ~s time .. The overlying . 
patavertebral muscles wIll then be sutured WIth absorbable 6-0 sutures, and the skin closed WIth skin clips. Anunals WIll be kept 
.-__ ~~~-.-__ ~-.-~ __ -.-~ __ ~ __________________________________________ ~ __ -,4 
wann with a heating pad or heat lamp (monitered with a thennometer) after surgery. Skins clips will be removed 7 days later. Special 
care will be taken to place food in the cage for easy access. The animais' bladders will be evacuated manually every 12 hours if the 
animais become unable to urinate due to the spinal cord damage (niost mice will require manual evacuation for the frrst 48 hours at 
least), and for prophylaxis ofurinary tract infections, aIl mice will receive gentamycin (1 mg! kg) administered subcutaneously once 
er day for 7 days. This prophylactie regimen was reeommended by the Reeve-Irvine Institute, University of California, where tbis 
model was developed, and has been discussed with the facility Veterinarian (Dr. Matsumiya). Less than 10% of the animaIs might 
be expeeted to beeome fully paraplegie. Mice will be weighed weekly, and those showing loss ofbody weight of 15%, wound 
dehiscence, pressure sores, dehydration or lethargy will be euthanized. 
- Analgesia (post operative), as per SOP (for 48 hours post-operatively) 
- Behavioral testing (as described above, every two days post-surgery) 
- Behavioral testing for hyperalgesia (Tail-withdrawal test: Mice are lightly restrained in a clothlcardboard "pocket." The 
protruding distal half of the tail is then dipped into a bath of circulating water thennostatically controlled at 49.0 ± 0.2°C. Latency to 
respond to the heat stimulus with tail flexion is measured to the nearest O.ls. Three separate withdrawallatency detenninations, 
separated by~Os, are made. Only non-paraplegic mice with good motor function in the tail will be assessed, and the water 
temperature is too low to cause tissue damage. Von Frey (VFl filament test of mechanical sensitivity: Mice are placed withln 
Plexiglas observation chambers (4 x 4 x 7 cm) on a metal mesh floor. Mechanical sensitivity is measured by determining the median 
50% foot withdrawal threshold with von Frey monofilaments (bending forces: 0.3,0.7, 1.6,4.0,9.8,22.0, and 53.9 mN; applied 
using a single, steady >1-sec application) using the up-down method ofDixon (Chaplan et al. 1994). AU mice will be tested in their 
front paws (as normal motor function is preserved in their front paws even immediately post-operatively, since the spinallesion is 
mid-thoracic). Only non-paraplegic mice with the mechanical ability to withdraw the hind paw will be assessed on their hind paws.) 
- Anesthesia - as per SOP 
- Stereotaxic surgery: injection of tracer dye to determine extent of nerve regeneration - as per SOP, and described in detail below. 
After a survival time of3-6 weeks animaIs will be deeply anesthetized as per SOP, and the skull over the region of the parietal cortex 
will be removed with the help of a fme motor drill. The dura will be incised and the underlying cerebral cortex injected with 0.1~1 of 
tracer per site in 6 sites. The tracer is a neuronal marker that will be taken up by nerve cells in the cortex and transported down their 
processes into the spinal cord. These injections will be done using a glass micropipette (tip size 50 ~). This technique is widely 
used to trace neuronal connections in the brain and spinal cord. After the injection, the skin closed with 5-0 sutures, and the mice will 
be kept warm with a heating pad or heat lamp (monitered with a thennometer). 
- Analgesia (post operative), as per SOP (for 48 hours post-operatively) 
- Euthanasia - as per SOP 
- Tissue collection 
The procedures are the same as the original protocol: 
IF NO, supply new endpoints that are different from the original protocol: 
.. ·b)Fof:'i~!ll:'~~î:f 
Include here ALL endpoints, incIuding the ones described in the original proto col as weil as new 
and changed endpoints in CAPS: 
Experimental endpoints: no changes: 
For the sciatic nerve surgery mice, the endpoint will be 3 weeks post surgery (by which time the mice are walking normally). 
For the EAE donor mice, the endpoint is 10 days post immunization for collection of activated T cells. 
For the EAE recipient mice, mice will be euthanized at days 14 or 30 days following fmal injection. 
For the SCI mice, 2 days post hemisection to determine local neurotrophin production in the spinal cord, or 3 weeks post hemisection 
to determine functional recovery, or 3 weeks post hemisection surgery, then 1 week after injection of tracer (total = 4 weeks) to 
determine nerve regenera,tion. 
For aU mice, the endpoint will OCCur when they are between 7 and 12 weeks old. 
Clinical endpoints: no changes: . ___ .. 
pain or distress is observed (lack of drinking, feedingor.grooming; hunched posture; piloerection; dehydration; lethargy), ode ... 
eight loss exceeds 20% (mice will be weighed weekly), orifwôund dehiscence or pressure sores develop, the animal will be 
ellthanized. .. . . 
8. Hazards (check here ifnoneareused:[gI) 
a) Are the hazards different from original protocol? (infections, radioactive, toxic, carcinogen, tumours) 
L--~" 
YESO NO[gl ifyes, supply details (material, risks, precautions): 
b) Have the celllines been tested for human and animal pathogens? YEs:D 
;: Jackson Labs, 
"Charles River 
C57BL/6 (B6) 
Strain 1: B6 (wild-type) mice 
EAE experiments: 
Treatment groups: 
1. EAB untreated 
2. EAB plus control Ab it. 
3. EAB plus Fas Ligand Ab it. 
Mice 
Jackson Labs Jackson Labs 
C57BL/6-Faslpr (lpr) C57BL/6-Faslg1d (gld) 
Females and males Females and males 
6-8 weeks 6-8 weeks 
117 117 
117 117 
4. EAB induced with T ceUs pre-treated with control Ab 
5. BAB induced with T ceUs pre-treated with anti-FasL Ab 
Recipient mice = 6 groups x 6 mice/group x 2 time points = 72 mice 
No:D None used:[gJ 
C57BL/6-Fasnu 1 (Fas-nuU) 
Females and males 
6- 8 weeks 
117 
117 
We have determined in previous experiments that 6 are required per group for statistical significance, since 
disease course is not always consistent between mice. 
Donor mice (as a source ofT cells), with 1 donor mouse / 2 recipient mouse required = 36 mice 
Sciatic nerve experiments: 
Treatment groups: 
1. sham surgery 
2. surgery plus control Ab 
3. surgeryplus Fas Ligand Ab 
3 groups x 5 mice/group x 3 experimentaLrepJiçates = 45 mice 
"pinai cord injury (sCI) experiments: 
Treatment Cl"r1'\111"\C' 
5 
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1. sham surgery 
2. surgery plus control Ab 
3. surgeryplus Fas Ligand Ab 
J groups x 8 mice/group x 3 time points = 72 mice 
Due to greater variation in spinal surgery compared with peripheral nerve crush, and occasional intra-operative 
death (less than 1 per group on average), the number ofmice per group is greater for SCI than for sciatic 
surgery. 
Due to the labour intensive nature ofthese experiments we only anticipate one experimental replicate per strain 
per year, on average. 
Total Strain 1 (B6 mice): 72 + 36 + 4S + 72 = 22S mice 
Strains 2,3 and 4 consist ofB6 mice bearing mutations in Fas or FasL. Bach ofthese strains will be used for 
sciatic nerve and SCI experiments in parallel with the wild-type mice as described above. Therefore, 
Total Strain 2, 3, and 4 (each) = 4S + 72 = 117 
Submit to your local Facility Animal Care Committee.·Please note that after two renewals, a full protocol needs 
to be submitted. 
This approval does no! imply tha! space will be made available. If a major increase of space needs is 
anticipated, please contact the appropriate animal facility manager. 
170'd ltllOl 
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(' iii) the protocol for decontaminating spills 
Bleach will be used to decontaminate sp01s, acoordins to the following protocol: 
1- ares. of spill contained 
2- spill Pbsorbed with papa towels 
3· area soak.ed with bleach 
4- towels disposed of in labels bags for autoclaving 
5· area washed. and nnsed 
An wastc will be deconmminated \Vith bleaeh and plastics will be disposed of in labelled bag.!:, which will then be 
autoclaved. 
• 
7. Does the protoc:ol present conditions (e.g. handlmg oflarge volumes or high concentrations ofpathogeDs) whieh could 
incr~e the hazards of the infectious agent(s)7 . 
NO 
8. Do the specifie procedures to be employed involving genetically engine.ered orgsnisms have a lmtory ofsafe use? 
NIA 
9. What precautions are being taken to reduce production ofinfectious droplets and aerosols? 
1 ~ No infectious material will he used 
2- AlI procedures are carricd out in laminaI' flow boods, which have been duly tested and certi.fied 
3. AlI procedures will be canied out by ttained personnel 
O. l 'cal List the bic ogit safety t-abinets to be \lScd. 
Building RoomNo. 
McInryre 1234 
Mcfnryre 1234 
170/170'd 9è917 86~ 1715 
Manufacturer ModelNo. 
ThermoFonna 1286 
Nuaire NU-42S-400 
3JI~~O INtI~9 HJ~tl3S3~ 
.~ 
Seriai No. Date Çenified 
23023-1261 ~(~ .~ 
SS37S C1J/~ __ -v 
TOTAL P.0:3 
81:51 900è-0è-Nnr 
r-\ 
( 
< MHi"<-~d-dIcl1cl4 14; 41:::l c.N~JlRONMENTRL SRt-E: TY OFF 
._---- _._---
iH) the protocol for decontaminating spills 
Bleach will he used to deeontamil'l.aœ spiUs, according ta the following protocol: 
1- ares of spiU eontained 
2- spill absorbe<! with paper towels 
3- area $oaked with bleach 
4- towels disposed of in labels bags for autoelaving 
5- area washed and rinsed . 
514 398 8047 P.03/03 
Ali v,"&Ste will oc d~ontaminated ... 'iih bleach and "l~Jt3 will be disposed of ùi labelled bags, wroich will thm be 
autoclaved. 
7. Docs the protoc:ol present conditions (c.g. handling of large volumes or rugh concentrations of pathogens) wbich could 
increase the h3:l:3rds of the infectious agent(s)? 
NO 
8. Do the specifte proeedures 10 oe employed involving gen.etica11y engineered organisms have a hlstol)' of saie use? 
NIA 
9. What precautions are being t.3Iœn 10 reduce production of infeetious droplets and aeroso1s? 
1- No inf~ous matcrial will be used 
2 .. Ail procedur~ are carrÎet:i out in laminar flow hood~ which have been duly ttsted and certi.fied 
3~ AIl prooedures wlll be camed out by ttained personnel 
P. = 
10. List the biololl:ica.ltafety cabinets to be used. 
Building RoomNo. Manufacturer ModelNo. Seriai No. 
Mdntyrt 1234 Thennoronna 1286 23023-1261 
McIntyre 1234 Nuaite NU·425-400 55375 
Date Ctrtified 
OS/2003 
0512003 
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